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Current Challenges in Atrial Fibrillation Ablation 
Abstract 
Dr Edward J Davies 
 
The ablative management of atrial fibrillation, despite a number of landmark discoveries, 
remains one of the most challenging fields in interventional electrophysiology. It is generally 
accepted that successful isolation of the pulmonary veins is a highly effective way of 
managing paroxysmal forms of AF. However, despite almost a decade of research into 
alternative lesion patterns, the solution to persistent AF remains beyond our grasp.  
A variety of strategies have been proposed to target key areas in the atria; these use various 
complex mapping systems, usually based on tailored lesion sets to try and improve 
outcomes. None have proven to be the golden bullet.  
We have investigated the role of a lesion set intended to alter the electrical properties of the 
posterior wall of the left atrium. Commonly known as the ‘box-set’, this pattern has shown 
promise in early studies and may provide some key insights into future developments.   
Surgical ablation using the Epicor system aims to deliver the box-set lesion, outcomes have 
previously been documented but each series has its limitations. In our series, very late 
outcomes are reported to show an 80% freedom from AF rate in patients with paroxysmal 
AF pre-operatively and only 20% in those with long-standing persistent forms. The reason 
behind this dramatic variation is explored through the invasive electrophysiologal 
assessment of both successful and unsuccessful cases. We report a clear correlation between 
the successful isolation of the posterior wall and long-term freedom from AF.  
Though surgical ablation may be an acceptable approach for some, the ultimate goal is a 
lesion set that can be delivered purely endocardially. We explore the outcome of one such 
empirical pattern based on the box-set concept delivered through linear catheter technology 
and report outcomes broadly similar to alternative patterns.  
 
 
   
VI 
TABLE OF CONTENTS 
1 GENERAL INTRODUCTION .......................................................................... 2 
1.1 The Normal Heart – Atrium ............................................................................... 2 
1.1.1 Anatomy of the atrium ............................................................................................ 2 
1.1.2 Physiology Of The Atrium ..................................................................................... 3 
1.1.2.1 Action Potentials ..................................................................................................... 3 
1.1.2.2 Electrical Conduction System ................................................................................ 4 
1.2 Atrial Fibrillation .................................................................................................. 5 
1.2.1 History ..................................................................................................................... 5 
1.2.2 Epidemiology .......................................................................................................... 6 
1.2.3 Signs and Symptoms .............................................................................................. 6 
1.2.4 Complications ......................................................................................................... 7 
1.2.5 Definitions and Classifications of Atrial Fibrillation ............................................ 7 
1.2.6 Mechanisms of Atrial Fibrillation .......................................................................... 8 
1.2.6.1 Initiation ................................................................................................................... 8 
1.2.6.2 Propagation – Remodelling .................................................................................... 9 
1.2.6.3 Propagation - Theories .......................................................................................... 13 
1.2.7 Management of Atrial Fibrillation ....................................................................... 17 
1.2.7.1 Rate vs. Rhythm Control ...................................................................................... 17 
1.2.7.2 Optimal Rate Control ............................................................................................ 18 
1.3 Ablative Strategies for Persistent Atrial Fibrillation .................................... 19 
1.3.1 Local Atrial Activity ............................................................................................. 19 
1.3.2 Linear Lesions ....................................................................................................... 21 
1.3.3 Targeting Ganglionic Plexi ................................................................................... 21 
1.3.4 Dominant Frequency Analysis ............................................................................. 22 
1.3.5 Targeting Rotors ................................................................................................... 22 
1.3.6 Targeting Areas of Low Voltage ......................................................................... 25 
1.3.7 Posterior Wall Isolation ........................................................................................ 27 
1.3.7.1 Surgical AF Ablation ............................................................................................ 29 
1.3.7.2 Hybrid Ablation Strategies ................................................................................... 31 
1.4 Thesis Outline ...................................................................................................... 32 
1.4.1 Aims ....................................................................................................................... 32 
1.4.2 Overview Of The Upcoming Chapters ................................................................ 33 
   
VII 
2 Late Outcome of HIFU epicardial ablation .................................................... 34 
2.1 Introduction ......................................................................................................... 34 
2.2 Methods ................................................................................................................ 37 
2.2.1 The Patients ........................................................................................................... 37 
2.2.2 Study Design and Investigations .......................................................................... 37 
2.2.3 Surgical Procedure ................................................................................................ 40 
2.2.4 Postoperative Management .................................................................................. 40 
2.2.5 Statistical Analysis ................................................................................................ 41 
2.3 Results ................................................................................................................... 41 
2.3.1 Paroxysmal AF ...................................................................................................... 43 
2.3.2 Persistent AF ......................................................................................................... 43 
2.3.3 Longstanding Persistent AF ................................................................................. 43 
2.3.4 Additional Interventions ....................................................................................... 46 
2.4 Discussion ............................................................................................................. 46 
2.4.1 HIFU and Alternative Epicardial Energy Sources .............................................. 49 
2.4.2 Study Limitations .................................................................................................. 50 
2.5 Conclusion ............................................................................................................ 51 
3 The Late Electrophysiological Consequences Of HIFU ............................... 52 
3.1 Introduction ......................................................................................................... 52 
3.2 Methods ................................................................................................................ 53 
3.2.1 The Patients ........................................................................................................... 53 
3.2.2 Recruitment ........................................................................................................... 54 
3.2.3 The diagnostic study ............................................................................................. 58 
3.2.4 Additional ablation ................................................................................................ 59 
3.3 Results ................................................................................................................... 59 
3.3.1 Free from Atrial Fibrillation – NSR ..................................................................... 59 
3.3.2 Free from Atrial Fibrillation – Atrial Flutter ....................................................... 62 
3.3.3 Atrial Fibrillation ................................................................................................... 66 
3.3.4 Additional Findings During AF Ablation ............................................................ 68 
3.3.4.1 Example 1 (Case 13) ............................................................................................. 68 
3.3.4.2 Example 2 (Case 7) ............................................................................................... 69 
3.3.5 Outcome from Additional Ablation Cases .......................................................... 73 
3.4 Discussion ............................................................................................................. 73 
   
VIII 
3.4.1 Previous Studies on the Box-set. .......................................................................... 76 
3.5 Findings of This Study ....................................................................................... 77 
3.6 Limitations of Study ........................................................................................... 78 
3.7 Conclusions .......................................................................................................... 79 
4 The Relationship between Left Atrial Pressure and Body Mass Index ..... 80 
4.1 Introduction ......................................................................................................... 80 
4.2 Methods ................................................................................................................ 81 
4.2.1 Statistical Analysis ................................................................................................ 81 
4.3 Results ................................................................................................................... 82 
4.4 Discussion ............................................................................................................. 85 
5 Persistent Atrial Fibrillation Ablation using the T-VAC ............................. 87 
5.1 Introduction ......................................................................................................... 87 
5.2 Methods ................................................................................................................ 88 
5.2.1 The Patients ........................................................................................................... 88 
5.2.2 Ablation Procedures .............................................................................................. 90 
5.2.2.1 Multielectrode Ablation Catheter (T-VAC) Technique ..................................... 90 
5.2.3 Post Procedural Management ............................................................................... 94 
5.2.4 Follow-up and Data Capture ................................................................................ 95 
5.2.5 Statistical Analysis ................................................................................................ 96 
5.3 Results ................................................................................................................... 96 
5.3.1 ‘De novo’ and ‘all procedures’ ............................................................................. 96 
5.3.1.1 Procedural Data ..................................................................................................... 97 
5.3.1.2 Long-term Outcome ............................................................................................. 98 
5.3.1.3 Time to First Event ............................................................................................... 98 
5.3.1.4 Redo Study Findings ........................................................................................... 101 
5.3.2 Complications and Procedural Safety ................................................................ 101 
5.4 Discussion ........................................................................................................... 102 
5.4.1 Duty-cycled Radiofrequency in Persistent AF .................................................. 102 
5.4.2 Posterior Wall Ablation ...................................................................................... 104 
5.4.3 Pulmonary Vein Isolation ................................................................................... 104 
5.4.4 Ganglionic Plexi .................................................................................................. 105 
5.4.5 Comments of Technique .................................................................................... 105 
5.4.6 Study Limitations ................................................................................................ 107 
   
IX 
5.5 Conclusion .......................................................................................................... 107 
6 Discussion ........................................................................................................... 108 
6.1 Original Findings .............................................................................................. 108 
6.1.1 Outcomes from HIFU Surgical Ablation .......................................................... 108 
6.1.2 Effectiveness of Box-set Patterns ....................................................................... 109 
6.1.2.1 Study Challenges ................................................................................................ 110 
6.1.3 Linear Catheter Ablation .................................................................................... 112 
6.1.3.1 Study Design and Recruitment ........................................................................... 112 
6.1.3.2 Ablation Using T-VAC ...................................................................................... 112 
6.2 Future Directions of Study .............................................................................. 113 
7 References .......................................................................................................... 114 
 
 
   
X 
LIST OF TABLES 
 
Table 2-1. Summary of previously published series reporting on AF ablation during 
concomitant cardiac surgery using HIFU. ................................................................................. 36 
Table 2-2. Baseline demographics of the surgical AF ablation population.. .......................... 38 
Table 2-3. Binary logistic regression showing impact of baseline variables on success 
rate of surgical ablation. ............................................................................................................. 45 
Table 3-1. Post-operative electrophysiological study participant demographics and 
operative data .............................................................................................................................. 56 
Table 3-2. Invasively assessed conduction times in milliseconds (ms) expressed as exit 
and entry between the pulmonary veins / posterior wall and coronary sinus. ......................... 57 
Table 3-3. Summary of the previous studies reporting invasive electrophysiological 
findings following ablation strategies intending to achieve posterior wall isolation.. ............ 75 
Table 4-1. Baseline demographics of study patient population ............................................... 83 
Table 4-2. Correlation values with the exclusion of specified patient groups ........................ 83 
Table 5-1. Baseline demographics of the T-VAC ‘de novo’ and ‘all procedure’ groups 
with inter group differences. ...................................................................................................... 89 
Table 5-2. ‘De novo’ and ‘all procedures’ outcomes (data expressed at n (%)). ................... 97 
Table 5-3. Summary of case series reporting outcomes from persistent atrial fibrillation 
ablation using duty-cycled radio-frequency ablation. ............................................................. 103 
   
XI 
LIST OF FIGURES 
 
Figure 1-1. Mechanistic theory of rotors.. ................................................................................ 16 
Figure 1-2. Examples of electrograms from the revised grading system. .............................. 20 
Figure 1-3. Example of rotor pattern and focal site involving RIPV in a patient with 
persistent AF demonstrated using body surface mapping techniques.. ................................... 24 
Figure 1-4. Example of left PV focal sites in a patient with paroxysmal AF ......................... 24 
Figure 1-5. 3D anatomical map of the LA showing the intended ablation sites .................... 28 
Figure 1-6. Showing the lesion set delivered by Todd et al. ................................................... 28 
Figure 1-7. (A) The bipolar clamp used to deliver bilateral PV antrial isolation. (B) The 
Cobra device, delivered thoracoscopically to deliver a single ring lesion in a box pattern 
and (C) the nContact tool which is delivered via the subdiaphragmatic approach to 
deliver sequential linear lesions across the posterior wall (D). ................................................ 30 
Figure 2-1. Circos plot representing the surgical HIFU ablation cohort.121 ........................... 39 
Figure 2-2. CONSORT diagram showing the flow of patients through the study period ..... 42 
Figure 3-1. Flow diagram showing the journey through the post-operative 
electrophysiological study. ......................................................................................................... 55 
Figure 3-2(A). With the circular mapping catheter (PV) placed flat on the posterior 
wall, an isolated premature atrial beat is seen showing electrical isolation of this region 
during sinus rhythm. (B) Circular mapping catheter (PV) in the right upper pulmonary 
   
XII 
vein and capture pacing from the coronary sinus, there is no evidence of conduction into 
the vein.. ...................................................................................................................................... 60 
Figure 3-3. In a patient with preoperative PAF and freedom from any recurrent atrial 
arrhythmia. .................................................................................................................................. 61 
Figure 3-4. In a patient with recurrence of paroxysmal left atrial flutter but freedom 
from atrial fibrillation. ................................................................................................................ 64 
Figure 3-5. In a patient with mitral valve replacement, pre-operative longstanding 
persistent atrial fibrillation and on-going symptomatic paroxysms of an atypical atrial 
flutter. .......................................................................................................................................... 65 
Figure 3-6. In a patient with aortic valve replacement, pre-operative long-standing 
persistent atrial fibrillation and on-going symptomatic paroxysms of atrial fibrillation. ........ 66 
Figure 3-7. In a patient with previous coronary artery bypass grafting, pre-operative 
longstanding persistent atrial fibrillation and on-going persistent atrial fibrillation. .............. 67 
Figure 3-8. Following successful ablation back to sinus rhythm, the circular mapping 
catheter on the posterior wall demonstrates an enclosed circuit most likely an atypical 
macro-reentrant in the presence of normal sinus rhythm on the surface electrograms. .......... 68 
Figure 3-9(A). Completion of the WACA lesion encircling the right-sided veins to join 
the roof line resulted in reversion to sinus rhythm. (B) Following completion of the 
bilateral PV-encircling lesions ................................................................................................... 70 
Figure 3-10. CARTO voltage map prior to catheter ablation energy delivery ....................... 71 
Figure 3-11. CARTO voltage map and superimposed catheter ablation energy delivery 
markers ........................................................................................................................................ 72 
   
XIII 
Figure 4-1. Example of a pressure tracing taken during AF ablation. .................................... 82 
Figure 4-2. Scatterplot representation of the association between BMI and mean LA 
pressure. ....................................................................................................................................... 84 
Figure 5-1. Fluoroscopy images of the T-VAC deployment .................................................. 93 
Figure 5-2. PVAC and T-VAC lesion patterns displayed using LocaLisa 3D system. ......... 94 
Figure 5-3. Kaplan-Meier plot showing the event free survival from all atrial 
arrhythmia between the all T-VAC procedures versus the de novo T-VAC group. ............... 99 
Figure 5-4. Kaplan-Meier plot showing the atrial fibrillation free survival of all T-VAC 
procedures versus the de novo group. ...................................................................................... 100 
   
XIV 
ABREVIATIONS 
AAD Antiarrhythmic drug 
ACT Activated clotting time 
AF Atrial fibrillation 
AFl Atrial flutter 
AP Action potential 
APD Action Potential Duration 
AT Atrial tachycardia 
ATP Adenosine triphosphate 
AVR Aortic valve replacement 
BMI Body mass index 
bpm Beats per minute 
Ca2+ Calcium 
CABG Coronary artery bypass graft 
CFAE Complex fractionated atrial electrograms 
CS Coronary sinus 
CTI Cavo-tricuspid isthmus 
CV Conduction velocity 
DAP Delayed afterdepolarisation 
DCCV Direct current cardioversion 
DF Dominant frequency 
ECG Electrocardiogram 
EF Ejection fraction 
EP Electrophysiological 
ESC European Cardiac Society 
GP Ganglionic plexi 
HIFU High intensity focussed ultrasound 
INR International normalised ratio 
IVC Inferior vena cava 
K+ Potassium 
LA Left Atrium 
LAA Left atrial appendage 
LTCC L-type calcium channel 
   
XV 
LV Left ventricle 
LVA Low voltage area 
MVR Mitral valve replacement 
Na2+ Sodium 
NYHA New York Heart Association 
LS PsAF Long-standing persistent atrial fibrillation 
LTCC L-type Ca2+ channel 
MAAC Multi-array ablation catheter 
MASC Multi-array septal catheter 
ms milliseconds 
NSR Normal sinus rhythm 
PAF Paroxysmal atrial fibrillation 
PIS Patient information sheet 
PsAF Persistent atrial fibrillation 
PV Pulmonary vein 
PVAC Pulmonary vein ablation catheter 
PW Posterior wall 
RIPV Right inferior pulmonary vein 
RSPV Right superior pulmonary vein 
RP Refractory period 
SA Sinoatrial 
SPSS Statistical Package for the Social Sciences 
SR Sarcoplasmic reticulum 
SVC Superior vena cava 
TV Tricuspid valve 
T-VAC Tip versatile ablation catheter 
WACA Wide area circumferential ablation 
3D Three dimensional 
   
1 
 
 
 
 
Current Challenges in Atrial Fibrillation 
Ablation 
 
 
 
 
 
“When the pulse is irregular and tremulous and the beats occur at intervals, then the impulse 
of life fades; when the pulse is slender (smaller than feeble, but still perceptible, thin like a 
silk thread), then the impulse of life is small.” 
 
Huang Ti Nei Ching Su Wen. Circa 220 BC 
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1 GENERAL INTRODUCTION 
1.1 The Normal Heart – Atrium 
The normal heart is comprised of two atria and two ventricles (left and right). The atria 
receive blood from the systemic circulation (right) and lungs (left) and contribute to the 
active filling phase of the ventricles. Because they operate at a low pressure, the atria are thin 
walled chambers when compared to the ventricles. Like all chambers of the heart, they are 
composed of three layers, the epicardium, myocardium and endocardium. All three are 
electrically active and in the normal healthy heart, function synergistically.   
1.1.1 Anatomy of the atrium 
The right atrium has three inlets, the inferior and superior vena cava (IVC, SVC) and the 
coronary sinus (CS). The outlet connects to the right ventricle via the tricuspid valve. The 
triangle formed by the TV, CS and IVC is referred to as the triangle of Koch.1 It is an area 
that conducts relatively slowly and is of significance in the pathogenesis of a right atrial 
macro-re-entrant circuit – typical (or ‘classic’) atrial flutter.  
The inlet to the left atrium (LA) is typically comprised of four (sometimes 3 or 5) pulmonary 
veins (PV). There is a blind ending sac arising from the LA known as the left atrial 
appendage (LAA). In normal sinus rhythm, this appendage is of limited clinical interest; it is 
sheathed in myocytic tissue and contracts to empty during each atrial systole. Its importance 
becomes more apparent when viewed under pathological conditions; it is a significant source 
of thromboembolic particles during certain atrial arrhythmia.  
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1.1.2 Physiology of The Atrium 
1.1.2.1 Action Potentials 
The AP is a rapid and temporary change in the electrical property of a cell that is conducted 
and propagated to the adjacent cells. This results in rapid transmission of electrical signals 
across tissue. There are 5 phases to the AP: depolarisation, early repolarisation, plateau, 
repolarisation and resting potential. Depolarisation (phase 0) occurs during a massive influx 
of Na+ ions through opened sodium channels. At the same time, the reduced membrane 
permeability to K+ is mediated through a drop in passage through the slow K+ channels.  
This depolarisation is maintained through early repolarisation and plateau (phases 1 and 2 
respectively) through the increase in influx of Ca2+ via slow voltage-gated Ca2+ channels. It 
is this influx of Ca2+ that is integral to the contraction of the myocyte. During the plateau 
phase, the inward current mediated principally through Ca2+ is balanced through the outward 
current from K+.  
Repolarisation (phase 3) is mediated by two mechanisms: i. an increase in the membrane’s 
permeability to K+ and ii. a decrease in the Ca2+ permeability which brings the membrane 
potential back towards the normal resting membrane potential of around -90mV.  
The action potential duration (APD) is split into 2 components: the absolute refractory period 
(ARP) and the relative refractory period (RRP). The absolute refractory period is the time 
between phase 0 depolarisation and midway through phase 3 repolarisation. During this 
phase, a second AP cannot be triggered.  Following on from this, the relative refractory is 
characterised by its ability to trigger a further AP if the stimulus intensity is high enough. 
The refractoriness of the atrial cell has been found to be in the region of 85 to 100ms during 
high frequency firing.2  
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1.1.2.2 Electrical Conduction System 
The complex synchronised cardiac conduction relies on both a specialist tree of conductive 
tissue and on conduction from adjacent myocytes via gap junctions.   
1.1.2.2.1 Sinoatrial Node 
Having the fastest escape rhythm in the heart, the sinoatrial (SA) node, first described 
anatomically in 1907,3 is primarily responsible for the regulating the heart rate.4 Specialist 
‘pacemaker’ cells are located near the junction of the RA and SVC. Though initially thought 
to be a simple dominate area of pacemaker cells, it has since been found to contain several 
major pacemaker components (head, centre and tail) surrounded by isolating structures 
situated all along the cristae terminalis.5 There are multiple sites within the RA that are able 
to initiate ‘sinus’ rhythm.6  
The sinus node itself has 4 preferential conduction pathways (SACP) which are responsible 
for conduction of electrical impulses into the surrounding atrial myocardium.5 The route of 
exit and propagation depends on the preferential SACP, the excitation wave spreads from the 
right atria to the left atria through the main intra-atrial musculature: either through 
Bachmann’s bundle and the coronary sinus musculature or through intra-atrial septum 
connections.7 
1.1.2.2.2 Crista Terminalis 
The cristae terminalis is comprised of cells that conduct electrical impulses from the SA 
node through the atrium until they reach the AV node.   There is a conduction delay inherent 
to the cristae that can act as a slow pathway – a critical component to re-entrant circuits that 
may result in organised atrial tachyarrhythmia. The cristae is a rich source of ectopy and that 
these ectopics may lead to both atrial tachycardia (AT) or AF.8  
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1.1.2.2.3 Atrioventricular Node 
The Atrioventricular (AV) node is located at the base of the atrial septum in the triangle of 
Koch. There are 2 ‘zones’ of cells making up the node, transitional and compact. The cells 
within the transitional zone are a histological and functional fusion of atrial myocytes and 
compact zone cells. This compact zone gives way to 3 posterior extensions: one in the 
direction of the CS (the ‘slow pathway’), one anteriorly near the compact zone (the ‘fast 
pathway’) and the third towards the mitral annulus (the left atrial extension). There is 
typically a gap of around 15mm between the putative fast and slow pathways that allows for 
ablation not resulting in complete AV block.  
1.2 Atrial Fibrillation 
1.2.1 History 
The condition characterized by an irregular pulse has roots in all the main ancient 
civilizations. Perhaps the earliest recorded description dates from as far back as 250BC given 
in Huang Ti Nei Ching Su Wen, the Yellow Emperor’s Classic of Internal Medicine. In 
1628, William Harvey, the first to correctly describe the circulatory system, was likely to be 
the first to describe fibrillation of the auricles of dying animals.9 It took a further 150 years 
for his theory to be replicated by Jean-Baptiste de Senac,10 described in relation to mitral 
valve disease. In 1909, Thomas Lewis, a close friend of the inventor of the 
electrocardiogram, William Einthoven, reported the first electrical description of pulsus 
irregularis perpetuus and correctly ascribed this chaotic rhythm as arising from fibrillation 
of the auricles.11 The beneficial effect of digitalis was first reported in the 1930s but the 
mechanisms and possible consequences of AF remained very much in debate until 1970 
when a computer model was used to demonstrate that the irregular ventricular response was 
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due to “randomly spaced atrial impulses of random strength reaching the atrioventricular 
node from random directions”.12 
1.2.2 Epidemiology 
Atrial fibrillation is a very common condition with a prevalence increasing with age; 8% of 
the over 75 population are affected.13 It is responsible for significant morbidity and mortality 
and as such has major health economic implications. Hypertension, rheumatic heart disease 
and heart failure were identified as common precursors in the Frammingham study, though 
in around one-third of patients, no clear cause is found. In 2010, an estimated 33.5 million 
people were affected worldwide (20.9 million males and 12.6 million females).14 
Traditionally, hypertension has been considered a strong risk factor for AF. The actual 
relative-risk is between 1.2 and 1.5, but because of the extreme prevalence in the global 
population, the overall effect is large with estimates suggesting that around 14% of cases are 
related to hypertension.15  
1.2.3 Signs and Symptoms 
Atrial fibrillation contributes to a patient’s morbidity and mortality regardless of symptoms. 
Many cases of asymptomatic AF are recognised as incidental findings during unrelated 
consultations with healthcare professionals. Unfortunately, many others present with 
thromboembolic events, such as stroke. Estimates suggest that between 5% and 35% of all 
AF cases are asymptomatic.16–18 
Patients may complain of ‘constitutional’ symptoms including tiredness and lethargy or 
others related to a rapid heart rate: palpitations, dyspnoea and chest pain. Some patients only 
develop symptoms during exertion; others have debilitating symptoms, even at rest.   
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The only sign of AF is an irregularly irregular pulse. However, there may be other signs 
pertaining to the underlying condition such as the mid-diastolic murmur of mitral stenosis or 
proptosis suggesting Grave’s disease.  
1.2.4 Complications 
Though thrombus arising from the LA can embolise to practically anywhere in the body, 
probably the most significant complication is a cerebral embolism leading to stroke.  
AF may lead to a reduced left ventricular ejection fraction; first described a century ago by 
James Mackenzie,19 it’s prevalence probably remains underestimated to the current day. The 
exact mechanism of tachycardia or AF mediated cardiomyopathy remains poorly 
understood. Groups working on animal models have reported myocardial energy depletion, 
myocardial ischaemia, alterations in the way calcium is regulated and extracellular matrix 
remodelling as potential theories for the observed effect.20  
1.2.5 Definitions and Classifications of Atrial Fibrillation 
AF is a supraventricular arrhythmia characterised by disorganised, chaotic contraction of the 
atria. Diagnosis is made when all three of the following surface ECG properties are seen: 
1. Irregular RR intervals 
2. A lack of distinct p-waves on the surface ECG  
3. A variable atrial cycle length of less than 200ms.21 
AF is classified depending on its temporal characteristics. Paroxysmal AF (PAF) is defined 
as recurrent (≥2) episodes that each last less than 7 days and terminate spontaneously. 
Persistent AF (PsAF) is defined as a single episode that lasts greater than 7 days. Should 
cardioversion be performed within 7 days of onset, it is classed as PAF if cardioversion 
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occurred within 48 hours of initiation, and PsAF if it was after.22 A third classification is that 
of  ‘longstanding persistent AF’ (LS PsAF), a continuous single episode lasting greater than 
one year.  Finally, when a joint decision has been made between the physician and patient to 
accept AF and make no further attempts at rhythm control, it is termed ‘permanent’. Where 
patients have episodes that fall across categories, it is recommended that the predominant 
class over the preceding 6 months is used (particularly in relation to the outcomes from 
ablation procedures).22  
1.2.6 Mechanisms of Atrial Fibrillation 
Characteristics of AF give clues to the underlying pathophysiology. Patients with new onset 
AF usually have one of 2 main clinical phenotypes; those that have frequent, short lived 
episodes and those that have episodes that last >48 hours and require either AADs or DCCV 
to restore sinus rhythm. The former likely arises from the firing of rapid focal triggers, which 
may or may not arise from the PV. Where the AF lasts greater than 48 hours, there is likely 
to be electrical and later anatomical remodelling involvement (discussed in 1.2.6.2).  
1.2.6.1 Initiation 
Initiation of automated activity is thought to be responsible for the triggering of AF. Inward 
movement of Na+ or Ca2+ can cause depolarisation of the cell. Should this depolarisation 
reach a threshold potential, automatic activity is produced and the cell will fire. When this 
process occurs before the next sinus beat (originating from the SA node) a premature atrial 
complex results.  
 
There are different mechanistic theories as to how these ectopic beats come about, though 
‘delayed afterdepolarisations’ are the predominant mechanism within the atrial tissue.  
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1.2.6.1.1 Delayed Afterdepolarisations 
Ca2+ is stored within the cell in an organelle called the sarcoplasmic reticulum (SR). Ca2+ 
entering cardiomyocytes through channels during the AP plateau triggers a massive release 
of Ca2+ from these SR stores via a specialist channel called RyR2.  This causes the cell to 
contract. During the following relaxation phase, this Ca2+ is removed from the cytosol back 
into the SR by an active pump, an ATPase.  When there is an abnormality with the RyR2 
channel, Ca2+ can leak into the cytosol inappropriately.  This calcium is handled by a cell 
membrane Na+/Ca2+ exchanger which will eject one Ca2+ ion in exchange for three Na+ ions; 
this creates a net depolarisation and subsequently a delayed afterdepolarisation. 
1.2.6.1.2 Pulmonary Vein Triggers 
The majority of episodes of PAF arise from triggers located within the PVs. This discovery 
was made in the seminal paper by Haissaguerre.23 The evidence to back up this theory not 
only lies in the electrophysiological observations of PV potentials at the time of ablation, but 
also in the considerable success that PVI has accrued in the ablative management of PAF. 
Series outcomes from PVI report success rates ranging from 66% to 89% at one-year follow-
up.22 However, there are cases where PAF ablation has failed despite successful, validated 
PVI. It is in these cases that non-PV triggers should be sought.8,24–27  
1.2.6.2 Propagation – Remodelling 
“AF begets AF”, a commonly quoted expression which neatly expresses what was first 
observed by M. Rosenbaum with the phrase “domestication of atrial fibrillation”.28 It is 
based not only on anecdotal observation by the physicians, but also on the prevailing disease 
pattern. Typically, AF will initially exist in the paroxysmal form and will be reliant on 
triggers for repetitive initiation. This form of AF typically involves episodes the last less than 
48 hours. However, after a period of time these episodes become more sustained. There are 
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four main physiological changes that occur during AF, which may lead to it progressing 
from paroxysmal to persistent.  Some processes are brought on by AF itself and others are 
related to commonly associated disease processes. Remodelling can be both electrical and/or 
structural, autonomic changes occur and calcium handling is altered. 
1.2.6.2.1 Electrical Remodelling  
Like all the cells in the body, ion channels, the properties of which can be altered by atrial 
remodelling, mediate the electrophysiological properties of atrial cells. There are three main 
aspects to this:  
• Down-regulation of the ICaL channel. 
During the action potential depolarisation, Ca2+ enters the cell through the L-type Ca2+ 
channel (LTCC). This in turn triggers a release of Ca2+ from the SR via the RyR2 channel. It 
is this large net increase in intracellular Ca2+ levels that initiate cellular contraction via 
myofilament movement.  
The levels of Ca2+ within the SR are dictated by net Ca2+ movement; inward via an active 
ATPase channel and outward via the RyR2 channel. The ATPase channel is inhibited by a 
subunit which, when phosphorylated, becomes dissociated. This happens under adrenergic 
stimulation or increased intracellular Ca2+ loading, which also leads to phosphorylation of 
RyR2 by protein kinase A. This adaptive mechanism responding to adrenergic drive 
increases the cardiac chronotropic and inotropic response. However, sustained Ca2+ loading 
causes abnormal diastolic RyR2 Ca2+ release.  This is achieved via a Na/Ca exchange pump 
responsible for the inward current causing phase 4 membrane depolarisation. These resulting 
afterdepolarisations have been described previously (see section 1.2.6.1.1).  
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During rapidly conducted AF there is a sustained increase in the level of intracellular Ca2+ 
which leads to certain self-defence mechanisms designed to defend against chronic Ca2+ 
overload. Ultimately this leads to down regulation in the gene coding for the LTCC29   
resulting in a decrease in the inward calcium current, maintenance of the AP Plateau, 
shortening of the AP duration and leads to an environment where re-entrant circuits become 
more likely. These re-entry circuits, particularly in a fibrosed substrate increase the 
likelihood of AF sustainability. 
• Up regulation of IK1  
The IK1 channel controls the principal background cardiac inward rectifier current and 
determines the resting potential and terminal phase 3 repolarization. These inward rectifier 
currents are a particularly important determinant of the putative types of re-entry circuits that 
maintain AF. Unfortunately IK1 is up-regulated during AF.30  
An alternative inward-rectifier current is responsible for some of the effects of acetylcholine. 
The IKACh channel is the key to the causative effect of enhanced vagal activation to in the 
promotion of AF – in part by reduction in the action potential duration, which again leads to 
an environment of putative rotor stability. Further activation of IKAChc channel results from 
AF induced atrial tachycardia and enhanced Ca2+ loading. 
• Up regulation of the small conductance calcium activated potassium channel 
Small conductance calcium-activated potassium channels, when activated, may shorten the 
APD. The genes KCNN1/KCNN2 and KCNN3 encode these channels.  A link has been 
found between KCNN3 single nucleotide polymorphisms and AF.31 It has been proposed 
that rapid atrial activation, typically seen in AF, may up regulate expression of small 
conductor’s calcium activated potassium channels which in turn contributes to AF 
maintenance and susceptibility.32 
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1.2.6.2.2 Structural Remodelling 
Many disease processes associated with AF act by causing atrial enlargement and secondary 
tissue fibrosis. There are a number of mechanisms by which fibrosis promotes AF; the 
interaction between cardiomyocyte and fibroblast is potentially arrhythmogenic by causing 
changes in the cardiomyocyte biochemistry. Also, the interruption of the fibre bundles within 
the LA wall can alter local conduction. There is a documented association between fibrosis 
and both AF incidence30,33,34 and the likelihood of failure of ablation procedures.35,36 
1.2.6.2.3 Autonomic Regulation 
There is a well-recognised pattern of AF, particularly in the young, which sees paroxysms 
triggering mostly at night. The autonomic nervous system is heavily implicated in both the 
initiation and propagation of AF.37 High vagal tone acts to enhance acetylcholine-dependent 
K+ currents, which leads to a reduction in the duration of the action potential. This stabilises 
re-entrant rotors and subsequently AF.38 In addition, adrenoceptor activation increases 
diastolic Ca2+ leak and promotes DAD related ectopic firing by hyperphosphorylating RyR2 
chnnels.39 This state of atrial sympathetic hyperinnervation can occur in PsAF.40  
Positive feedback loops may arise through autonomic remodelling and can act to promote 
AF persistence and recurrence.40 The role that targeting the ganglionic plexi has in the 
ablative management of AF is discussed in section 1.3.2.6.  
1.2.6.2.4 Calcium handling abnormalities 
Abnormal Ca2+ handling may be proarrhythmic through the increase in DAD induced 
ectopy. LS PsAF is associated with an increased incidence of arrhythmogenic DAD 
triggered activity.41 Hyperphosphorylation of RyR2 leads to an increase in sarcoplasmic Ca2+ 
leak.41 Meanwhile, up-regulation in the Na+/Ca2+ exchange increases the magnitude of 
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delayed afterdepolarisation generating inward currents for any given amount of aberrant 
Ca2+ release, thereby magnifying the effect from the leaked Ca2+. Sustained and rapid atrial 
activation appears to cause AF induced remodelling through increase in Ca2+ cytoplasmic 
loading.  
While LS PsAF is likely maintained by complex multiple circuit re-entry,30,33,42,43 ectopic 
activity may contribute by reinitiating AF should it terminate spontaneously or via medical 
intervention. Recent work points to a predisposition to DADs in patients with PAF that 
likely plays a more primary role in arrhythmogenesis.44 The principal underlying 
mechanisms include increased SR Ca2+ load due to hyperphosphorylation of RyR2 and 
abnormalities with RyR2 itself.44  
1.2.6.3 Propagation - Theories 
The basic mechanistic principles behind the competing AF theories are based around 
ideas developed nearly a century ago.45 Three such theories became mainstream: rapidly 
discharging atrial ectopic foci, single re-entry circuit and multiple functional re-entrant 
circuits. In the multiple-wavelet model (see 1.2.6.3.1), atrial irregularity is a 
consequence of the arrhythmia mechanism. For the rapid focal and single-circuit 
mechanisms, irregularity is proposed to arise from interactions between wavefronts 
produced by the primary generator (the ectopic focus or primary re-entrant circuit) and 
the spatially variable refractory properties of atrial tissue (‘fibrillatory conduction’). 
In order to develop effective pharmacological and ablative strategies, an appreciation of 
the predominant mechanism is paramount.  
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1.2.6.3.1 Multiple Wavelets 
The multiple wavelet theory was the first to become mainstream. The work of Moe et al.,46 
emphasized the role of multiple wavelets in the propagation of AF. A familiarity of the 
‘wavelength of re-entry’, developed by Allessie et al. is important in understanding the 
multiple wavelet concept.47,48  
The wavelength is the distance travelled by an electrical impulse in one refractory period, 
and is calculated as the product of the refractory period (RP) and the conduction velocity 
(CV). If the pathlength of a potential circuit is smaller than the wavelength, the impulse will 
meet its tail in a refractory state and subsequently terminate. Therefore, the wavelength is the 
shortest pathlength that can sustain re-entry. 
According to the ‘leading circle’ hypothesis of Allessie et al.,47 functional re-entry will 
naturally establish itself in a pathlength the size of the wavelength. Wavelets behave as 
reentrant circuits. Therefore, the number of wavelets that can co-exist is proportional to LA 
size and the wavelength. When the wavelength decreases, so too does the minimum circuit 
size, which in turn increases the number of circuits that can be accommodated. This favours 
the formation of multiple wavelets and subsequently AF propagation. Based on this theory, 
the primary pharmaceutical approach to AF has been to increase the RP (and thereby the 
wavelength), limiting the number of wavelets to a point whereby AF can no longer be 
sustained. 
Interventions that limit the ability of these multiple wavelets to self-sustain include drugs that 
increase the RP and surgical division of the atria into electrically isolated areas. 
An observation incompatible with leading circle theory is the response of AF to 
antiarrhythmic drugs that block Na+ channels. Such agents are effective in terminating AF, 
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but according to leading circle theory should promote AF because they decrease conduction 
velocity and thereby decrease the wavelength. 
1.2.6.3.2 Focal Discharges 
Nearly 2 decades ago, Haissaguerre first reported the prominence of the PVs as dominant 
sites of ectopy, triggering PAF.23 To date, the role of PV and non-PV ectopy in PsAF is less 
certain.23 Focal impulses are defined by “centrifugal activation contours (isochrones) from 
an origin”.49 Ectopic mechanisms would be susceptible to drugs that suppress automaticity 
and to targeted destruction of ectopic foci by surgery or catheter-based approaches.  
A recent study looked at the role of ‘arrhythmogenic foci’ manifest through isoproterenol 
administration in PsAF ablation cases. They report that in the pre-ablation setting, 89% of 
their cases had PV foci and 54% non-PV. Following on from an “aggressive” ablative 
strategy only 41% had demonstrable foci at any site. Those patients with on-going foci had a 
50% of AF recurrence at 2.5-year follow-up whereas in those with no foci, the rate was only 
26%.  
It may be that these ectopic foci encourage PsAF by acting as a driver or by reintroducing it 
when it terminates.50 A third possibility however is that these foci are merely a marker of an 
advanced disease process within the substrate and do not play a mechanistic role.50 Further 
work is needed to delineate the importance of these foci in PsAF to guide future ablative 
strategies.51  
1.2.6.3.3 Rotors 
Rotors are a form of spiral wave and were first described in ‘myocardial fibrillation’ in the 
early 1990s,52 when they were linked to the characteristic ECG changes seen in ventricular 
fibrillation.53 They have since been proposed as a driving force behind PsAF. Initial attempts 
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to use isochronal (activation) mapping did not detect stable rotational circuits in  AF54 until 
complex signal analysis known as phase mapping was applied.55  
Several types of reentry exist; spiral waves represent one specific form. The central core 
from which the spiral waves emanate is termed a ‘rotor’ and meanders as it pivots around 
‘unexcited but eminently excitable tissue’.56 Critical to the action of rotors is the extreme 
wavefront curvature thet they exhibit. This curvature increases as conduction slows towards 
the ‘core’ and the small (curved) excitable gap that exists between head and tail of the 
wavefront eluding standard entrainment maneuvers.57 Rotors are thus defined using three 
key characteristics (Figure 1-1).  
• Extreme wavefront curvature at the core where head meets tail.  
• An excitable and precessing core.  
• A highly variable reentrant wavelength, with a usually undetectable excitable 
gap.  
 
Figure 1-1. Mechanistic theory of rotors. The solid line represents the wavefront, in this 
case moving anticlockwise. The dashed line is the wave tail. The velocity vector is 
represented by the solid arrows and the so called ‘phase singularity’ is shown by *. 
Reproduced from Pandit et al. with permission.56 
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Single-circuit re-entry should be suppressed by drugs that prolong the refractory period and 
inhibit re-entry, and by ablating key components of the re-entrant pathway. The role of focal 
impulse and rotor mapping and ablation is discussed in section 1.3.5. 
1.2.7 Management of Atrial Fibrillation 
The management of AF is a dynamic process which should be discussed and agreed upon 
between patient and physician. There are several important strands that need to be addressed 
at varying times throughout the management journey. Symptoms should be assessed and a 
cause found. For example, palpitations may be as a result of poor rate control; breathlessness 
could be secondary to impairment of LV function or inappropriate chronotropic responses 
and poor energy levels may be a ‘constitutional’ symptom of AF itself. Secondly, an 
objective assessment of the LV systolic and diastolic function will guide subsequent 
management decisions. Depressed systolic function may be due to poor rate control, 
irregular RR intervals or the primary cause for the AF. Thirdly, the individual 
thromboembolic risk should be assessed and anticoagulants administered where appropriate.  
1.2.7.1 Rate vs. Rhythm Control 
The decision of rate versus rhythm is complex and dynamic. Experience is needed to 
formulate and guide patients through appropriate management strategies. Important variants 
affecting this process include the duration and severity of symptoms, co-morbidities, LV 
function and other structural abnormalities, and arguably, the thromboembolic risk.  
There have been several studies published investigating the advantages of either a rate or 
rhythm control strategy. The largest of these was the Atrial Fibrillation Follow-up 
Investigation of Rhythm Management (AFFIRM) trial.58 Including over 4000 patients, they 
found no difference in all cause mortality (primary endpoint) or stroke rate between the 2 
groups.  
   
18 
Rate control was judged to be non-inferior to rhythm control in the RAte Control versus 
Electrical cardioversion for persistent atrial fibrillation (RACE) trial.59 The population of 
patients with PsAF and LV function <35% were investigated in the Atrial Fibrillation and 
Congestive Heart Failure (AF-CHF) study. In patients with AF and congestive heart failure, 
a routine strategy of rhythm control was not found to reduce the rate of death from 
cardiovascular causes, as compared with a rate-control strategy.60 
These three studies were performed between 2002 and 2008 in an era when ablative 
technologies for managing AF were in their infancy. Furthermore, a subgroup analysis of the 
AFFIRM trial suggested that the benefit from being in NSR was counterbalanced by the risk 
of adverse side effects from the AADs.61 It was proposed that “if an effective method for 
maintaining NSR with fewer adverse effects were available, it might be beneficial”.61 This 
statement lends support to the concept of invasive management of AF. These will be 
discussed in depth in section 1.3.   
1.2.7.2 Optimal Rate Control 
The optimal rate for a patient in PsAF is often thought to be similar to a person in NSR, i.e. 
between 60 and 100bpm. However, this is based on little more than intuition. Furthermore, 
as a result of the loss of atrial systolic contraction, it may well be that a higher than normal 
heart rate is physiologically appropriate. Through randomisation into either a strict (<80bpm) 
or lenient (<110bpm) rate control group, the RACE II study investigated this issue in over 
600 patients.62 Strict rate control conferred no advantage in any of the endpoints including 
mortality, hospitalisation or stroke rate, heart failure progression or, importantly, symptoms.  
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1.3 Ablative Strategies for Persistent Atrial Fibrillation 
Ablative technologies revolutionised the management of many types of cardiac arrhythmia 
by the mid-1990s. It was only more recently when reliable results were achieved for PAF 
and to this day, the results from ablation in PsAF remain disappointing.63 
1.3.1 Local Atrial Activity 
The possibility of there being key areas of substrate responsible for AF perpetuation led 
investigators to look for such critical area markers. In 2004, a study defined Complex 
Fractionated Atrial Electrograms (CFAE) as “atrial electrograms that have fractionated 
electrograms composed of two deflections or more, and/or perturbation of the baseline with 
continuous deflection of a prolonged activation complex over a 10s recording period”.27 
These have since been further classified into 6 grades of fractionation ranging from grade 1 
“uninterrupted fractionated activity (defined as segments ≥70 ms) for ≥70% of recording and 
uninterrupted ≤1 s” to grade 5 “discrete simple electrograms (≤4 direction changes)”, (Figure 
1-2).  
By using electroanatomical mapping systems, it is possible to map and subsequently ablate 
these CFAEs. The landmark 2004 study by Nademanee et al. reported on the outcome from 
this strategy in a patient group comprising 121 patients. By ablating only on sites of CFAEs 
(and importantly without performing PVI) they reported a 76% one-year freedom from AF 
rate after a single procedure and 91% after 2.27 Subsequent studies have failed to replicate 
these promising results.64 
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The exact underlying mechanism responsible for CFAEs remains unclear.  Indeed, the 
presence of fractionated electrograms are normal findings in the left atrium during sinus 
rhythm owing to wavefront collisions.65  However, it is clear that ablation at these CFAE 
sites can result in slowing, termination, and long-term freedom from AF.64 Although the 
initial reports of this technique were encouraging, this strategy has not been universally 
successful. This may in part be due to the widespread distribution of CFAE within the LA, 
which often requires extensive ablation.66  
CFAE sites may represent areas of passive atrial activation or collision of wavefronts.67 As 
such, some of these sites may represent critical areas for the maintenance of AF whereas 
others may merely be bystanders.  
Initially Grade 5 was divided into normal electrograms which were
rapid (cycle length !120 ms) or slow (cycle length .120 ms), as a
cycle length of 70–120 ms has generally been included as criteria for
identifying CFE in clinical trials.3,19 However, on testing application of
the classification system (see what follows), this distinction was
found to be redundant. When the cycle length was ,120 ms, the
deflections would often fall within 70 ms of the last and hence were
classified as continuous fractionation. This would then be classified
as Grade 1, 2, or 3 depending on the proportion of the sample occu-
pied by this continuous fractionation. Hence, this has been removed
from the classification system.
Application of the classification system
We sought to examine whether the electrogram classification system
could be accurately applied during cases by rapid online VI. Electrograms
recorded for 10 swere viewedon the computer-based recording system
and graded by an experienced electrophysiologist. It has been demon-
strated previously that recordings of 5 s or greater are adequate for
determining the duration and characteristics of CFEs.20 Variable times
have been used in the literature ranging commonly from 2 to
10 s.12,20–22 We used the maximum analysis time (10 s) to ensure accu-
rate results. One hundred electrograms over 10 patients (10 per case)
were chosen at random from those graded during the case and subjected
to detailed manual analysis offline by a second investigator blinded to the
previous results. These results were then c mpared.
As CFE can be consistent, fleeting, or cyclical,9,10,22 the proportion
of a sample that is fractionated can vary which may affect the grade
determined. Over the short term, however, automated assessment
of samples longer than 5 s has yielded consistent results compared
with longer samples.20 To determine the consistency of fractionation
and grade when shorter samples were analysed, the percentage of
the sample that was fractionated and the grade determined by MM
were calculated for the first 3 s, then recalculated adding successive
seconds up to 10 s. The absolute percentage difference in fractionation
compared with 10 s was then calculated. Agreement in grade was also
compared with 10 s.
Validation of commercial automated detection systems
As electrogram appearance may be altered by differences in amplifica-
tion and filtering of signals between systems, validation of automated
CFE detection systems was done by viewing electrograms on the 3D
mapping systems. The same sample analysed by the mapping system
was graded by VI. Electrograms were graded offline by VI on the
mapping system and compared with the automated result for the
same sample. As this process is slightly different to the process of
grading live during cases, the validation process was repeated. In
Figure 2 Examples of electrograms from the revised grading system. Electrograms are truncated for brevity but are representative of the 10 s
samples analysed. (i) The example for Grade 1 shows uninterrupted fractionated activity without pause at the isoelectric line for "70 ms lasting
1.29 s. (ii) The example for Grade 2 shows fractionated activity which is interrupted by pauses at the isolelectric line of "70 ms, but still occu-
pying .70% of the recording. (iii) The example for Grade 3 shows intermittent fractionated activity which occupies between 30 and 70% of the
recording. (iv) The example for Grade 4 shows complex electrograms ("5 deflections) which are discrete lasting for ,70 ms. Towards the end
of this sample, some complexes merge to last 320 ms (i.e. longer than 70 ms) and hence this part of the recording is considered fractionated.
However, this is still Grade 4 as ,30% of the sample is fractionated. (v) Grade 5 shows discrete electrograms (i.e. ,70 ms in duration and !4
direction changes). There are two xamples of far-field ventricular electrograms marked on this trace which can be easily distinguished from
near field atrial electrograms. Grade 6 shows scar with no discernible deflections.
Visual and automated characterization of CFE 1589
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Figure 1-2. Examples of electrograms from the revised grading system. 
Fractionation ranges from Grade 1 (fractionated activity defined as continuous 
deflections without pause for ≥70ms occupying >70% of the tracing) to Grade 5 
(discrete (<70ms) and simple (≤4 direction changes) electrograms). Grade 6 
represents scar with no discernable deflections. Reproduced from Hunter et al. with 
per ission.134 
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1.3.2 Linear Lesions 
The placement of various linear lesions for the ablative management of PsAF has been 
studied. The 2 most commonly deployed are the left atrial ‘roof line’ and ‘mitral isthmus 
line’, though others have been applied.68,69 Though there is some evidence that linear lesions 
can enhance the outcome for ablative procedures,70 the evidence is not yet compelling and 
such a strategy is not without risks.71 If an incomplete lesion is deployed, it may act as an 
area of slow conduction leading to the manifestation of macro-reentrant circuits.  
In 2015, the STAR-AF 2 study compared the outcome between 3 different ablation 
strategies; PVI alone, PVI plus CFAE ablation or PVI plus linear lesions (roof and mitral 
isthmus). At the 18 month follow up, there was no statistical inter-group difference in either 
the primary outcome of AF recurrence or the secondary outcome of atrial arrhythmia 
recurrence. Post-hoc analysis analyses showed that the group assigned to PVI plus linear 
lesions had a significantly higher incidence of arrhythmia recurrence without an AAD 
compared to PVI alone.71 
1.3.3 Targeting Ganglionic Plexi 
The intrinsic nervous system of the heart is formed by a complex network of nerves which 
join to form ganglionic plexi (GP) in areas typically sited in the epicardial fat around, but not 
exclusive to, the LA. The causative association between the autonomic nervous system and 
AF has long been described.72 A study looking at the effect of adjunctive complete vagal 
denervation during PVI procedures found it to significantly reduce AF recurrences at 12 
months.118  
Anatomical studies suggest that the majority of GP either overlay or are adjacent to the 
PVs.73 Over the past decade, there have since been many, relatively small studies, looking 
into the effect of different iterations of PVI and GP ablation. GPs have been identified both 
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anatomically and through high frequency stimulation techniques.74–78 PVI ablation alone 
resulted in a lower recurrence rate of AF compared with the rate after anatomically-guided 
selective GP ablation.76,77 By contrast, other studies have found that anatomical GP ablation 
followed by PVI ablation resulted in better clinical outcomes than with PVI ablation 
alone.70,71  
1.3.4 Dominant Frequency Analysis 
Dominant frequency (DF) analysis is a mathematical method of identifying areas of 
substrate critical for the initiation and perpetuation of AF.81 It can be considered as an 
extension of CFEA mapping and may mechanistically represent rapid local re-entrant 
circuits, focal ectopic sources or wavefront collision.82,83 This process enables the 
identification of areas which ‘fire’ at high frequencies in an environment of irregularity. 
Areas showing a higher dominant frequency are thought to represent areas that are critical to 
AF maintenance and therefore represent potentially useful ablation sites.  
1.3.5 Targeting Rotors 
A description of a rotor is provided in section 1.2.6.3.3. These electrical rotors and focal 
impulses are thought to contribute to AF perpetuation.43,49,84–87 In experimental models, 
rotors or focal impulses become disorganized and develop into AF.43,85 Although the rotor 
itself may be stable and regular, the heterogenicity of the surrounding substrate causes 
fibrillatory conduction.85  
Given these findings, clinical computational approaches to mapping have been developed. 
These involve the physiological interpretation of fibrillatory wave activity by analysing 
widely sampled atrial sites through the insertion of a basket catheter placed sequentially in 
both atria.49,87 Spatiotemporal analysis can be performed allowing propagation cines to be 
constructed.87 These digital electroanatomical atrial maps, created using novel software 
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mapping systems can help identify localized sources of AF in the form of sustained electrical 
rotors and repetitive focal impulses in humans.87 In this study, rotors were defined as 
“rotational activity around a centre, and focal impulses were defined as a point of origin of 
AF from surrounding diastole”.87  
In the CONFIRM trial,49 computational maps were used to demonstrate that ablation of AF-
sustaining sources terminated or consistently slowed persistent and paroxysmal AF in 82% 
of patients after 2 years.49 Interpretation of the CONFIRM study and other studies using this 
technology has been challenging because of the heterogeneous patient population. In 
particular, the cohort was made up of patients with PAF, PsAF or LS PsAF and some 
patients had previously undergone a LA ablation procedure. Despite the compelling data 
from the CONFIRM trial, invasive mapping of AF mechanisms has limitations.  
Non-invasive electrocardiographic imaging has also been used to investigate the 
mechanisms underlying AF.88 One such technique utilizes a jacket that contains 256 body 
surface electrodes sited around the patient’s torso. Each electrode contains a marker which 
records its location on a CT scan. This data is then digitalized and transferred to one of the 
commercially available 3D mapping packages.  
The first study to report on this non-invasive mapping technique reported on the frequency 
of each different putative mechanism. The most-common patterns of AF were multiple 
wavelets (between 1 and 5 wavelets seen in 92% of cases), many of which also had PV 
(69%) and non-PV (62%) focal sites. Rotor activity was seen infrequently (15% of cases). In 
patients in whom potential rotor activity was observed, these rarely made one full rotation 
before breaking into less-organized wavelets.88 That said, the areas of rotor activity were 
consistent over multiple mapping attempts. Interestingly, rotors were only seen in patients 
with PsAF.  
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Figure 4. Example of left PV focal sites in a patient with paroxysmal AF (Movie 4 in Online
Supplement)
Panels A and B show two examples of ECGI isochrone maps of both atria (posterior view)
at select times during AF. A focal site is frequently seen near the left PV's (stars) with radial
activation spread. Conduction delay (crowded isochrones) is seen in posterior LA. Online
Movie 4 demonstrates these patterns with continuous AF imaging, with 1 to 2 simultaneous
wavelets predominantly traveling left-to-right.
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Figure 5. Example of rotor pattern and focal site involving RIPV in a patient with persistent AF
(Movie 5 in Online Supplement)
Panel A shows a reference image of both atria in posterior view. Panel B shows six time-
lapse ECGI images of activation wavefronts (red) in a rotor pattern using RIPV as a pivot.
White arrows show the path of wavefronts down the posterior LA and around the RIPV. At
50ms, activation exits the RIPV in a radial pattern. Online Movie 5 shows two to three
simultaneous wavelets, frequently using RIPV as a pivot.
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Figure 1-3. Example of rotor pattern and focal site involving RIPV in a patient with 
persistent AF demonstrated using b dy surf ce mapping techniques. A reference showing 
the posterior wall of the left atrium is provided in panel A. Panel B shows six time-lapse 
electrocardiographic imaging maps of activation wavefronts (red) in a rotor pattern. In this 
example, the RIPV acts as a pivot. White arrows show the path of wavefronts down the 
posterior LA and around the RIPV. Reproduced from Cuculich et al. with permission.88  
 
Figure 1-4. Example of left PV focal sites in a patient with paroxysmal AF. Shown are 
two examples of isochrone maps f both atria (posterior view) t select times during AF. 
Here, a focal site is seen near the left PVs (*) with radial activation spread. Conduction 
delay (crowded isochrones) is se  in p sterior LA. Reproduced from Cuculich et al. with 
permission. 88 
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1.3.6 Targeting Areas of Low Voltage 
It has been proposed that diseased myocardium can be identified through areas of low 
voltage (LVA). Furthermore, it is possible that these areas are important for AF propagation 
and as such could represent markers for effective ablation targets.89 The presence of LVA are 
a significant predictor for AF recurrence following an ablation procedure.90 There are a 
number of variables that need to be taken into account when assessing LVA:  
• Unipolar / bipolar. Unipolar measurements record signals amplitude between the 
electrode (local event) and a distant cathode (usually a skin pad). They have the 
advantages of showing signal direction but suffer significant artefact. Bipolar 
catheters record the voltage of myocardium between a proximal and distal 
electrode. As such, the resolution of bipolar mapping is restricted by the spacing 
between these 2 electrodes, which will range between 3.5 and 7.5mm for a 
standard mapping catheter depending on the angle of incidence. Smaller spaced 
catheters are available which may be of use in defining areas of diseased 
myocardium with a higher resolution, demonstrating areas of heterogenicity 
which would potentially have been missed.91 Most centres targeting areas of low 
voltage will use bipolar mapping. Catheter contact force and orientation will 
affect recorded voltages. It is possible, especially with multi-electrode catheters, 
that low voltage will be recorded when in fact there was poor tissue contact. 
Newer generations of mapping systems attempt to reduce this by utilising the 
contact force measured by catheter tips to ensure good tissue contact or by only 
recording voltage samples when the mapping catheter is within 5mm of the 
anatomy shell.  
• Rhythm. Centres predominately map areas of low voltage in NSR. There can be 
marked variations between voltages obtained while in atrial arrhythmia and 
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NSR,92 although a recent study has demonstrated a linear relationship between 
the voltage measured in  NSR and AF; this is an area needing further research.93   
There is debate in the literature as to the definition of ‘low voltage’ within the LA. Several 
studies have used a value of >0.5mV to define normal tissue, diseased myocardium to be 
between 0.2 and 0.5mV and <0.2mV as likely scar.90,94–96 
Some studies have reported a relationship between scar identified on gadolinium enhanced 
CMR and LVA though this remains a controversial area. An interesting study examined the 
correlation in patients with previous ablation lines and found only a very weak correlation 
(r=-0.17) between the 2 measurements.97 Other studies have suggested that the degree of 
fibrosis in the left atrium can help predict ablation outcome.89,98,99 
In 2014, Rolf et al. described using this technique in 178 patients with PAF or PsAF.96 
Following standard WACA, they identified LVA whilst in NSR and targeted these, either 
through ‘boxing off’ or by homogenising with ablation delivered over the whole area.  
There are two particularly interesting points to this study. Firstly, is the distribution of the 
LVA. The LA roof, posterior and antero-septal wall were most commonly affected. Many of 
these areas are frequently covered by the traditional box-set pattern (described in paragraph 
1.3.7) and would have been influenced by this empirical approach; though many of the 
septal areas may not have. Secondly is this group’s assertion that PAF and PsAF should in 
fact be treated as one and the same with regards to ablation strategy and that these areas of 
low voltage should be sought in all AF ablation cases regardless of phenotype.  
There is a marked discrepancy between LVA and those of focal impulses / rotors suggesting 
that the 2 techniques are mapping different pathophysiological processes.100 
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1.3.7 Posterior Wall Isolation 
The posterior wall of the left atrium has repeatedly been identified as one of the key substrate 
areas for AF activity.96,101 Previously, we have discussed the major competing mechanistic 
theories of AF. Furthermore, we have shown examples of studies where these individual 
mechanisms have been targeted during ablation procedures. Particularly in the PsAF group, 
none of these mechanistic strategies have shown significantly superior outcomes.71  
An entirely different conceptual strategy is to accept the fact that the PW and PVs harbour 
the bulk of AF substrate. Thus, a potentially effective empirical technique is to isolate this 
whole area en bloc. The first group to attempt this was lead by Karl Heinz Kuch in 1999.102 
They planned to deliver a single ring of ablation scar anterior to the pulmonary veins in 13 
patients (Figure 1-5). Unfortunately, the catheter technology at the time was unable to 
deliver the full lesion set reliably and all 13 patients suffered AF recurrence.  
Four years later in 2003, Todd et al., reported on a series of patients in whom the same lesion 
set was delivered through a combination of surgical (incision) and cryo-ablation.103 The 
outcome was much more rewarding; only one of the 14 patients suffered a recurrence of AF. 
A subsequent EP study in this one remaining patient identified a gap in the cryo line which, 
when ablated, resulted in AF freedom.  
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Right Atrial Procedure
Catheters positioned in the right atrium included a Jackman catheter
advanced into the coronary sinus, a 7-French catheter with 20
electrodes (A20, Cordis Webster) placed along the lateral right atrial
(RA) wall, and a His bundle catheter. The NAVI-STAR catheter was
introduced by way of the right femoral vein or the right internal
jugular vein.
To enable ablation in the right atrium during coronary sinus
pacing, all efforts were undertaken to restore and maintain sinus
rhythm throughout the procedures. RA lesions included 3 lines
(Figure 2). The first line bridged the isthmus between the tricuspid
annulus and the ostium of the inferior vena cava (isthmus line). The
second line connected the ostium of the superior vena cava with the
anterior aspect of the tricuspid annulus (anterior line). The third line
was begun at the ostium of the inferior vena cava and directed toward
the ostium of the superior vena cava (intercaval line).
An intended gap of 2 to 3 cm was left in the superior part of the
intercaval line in all patients; exceptions were patients in whom
persistent gaps in the anterior line could not be closed. In those
patients, the intercaval line was intentionally closed.
The following modalities were used to validate the completeness
of RA linear lesions during coronary sinus pacing. Conduction block
across the isthmus line was assessed using the conventional criterion
of a change in the activation sequence recorded by the A20 catheter.6
To validate the completeness of the anterior and intercaval lines, the
CARTO activation and propagation map features were used. When-
ever unintended gaps were found along the ablation lines, current
was again applied. If single potentials persisted, the line was
regarded as incomplete.
Follow-Up
Postablation, a 12-lead ECG was recorded daily, and $1 Holter
recording (48-hour) was taken. Transthoracic echocardiography was
repeated to monitor procedure-related pericardial effusions. Overlap-
ping with continued heparin infusion (partial thromboplastin time, 60
to 100 s), anticoagulation therapy with Coumadin (international
normalized ratio, 2 to 3) was initiated.
After hospital discharge, $1 ECG (12-lead) and 24-hour Holter
recording were obtained at months 1, 3, and 6. During follow-up,
patients were asked to report all episodes of recurrent symptoms
suggestive of AF.
Study Endpoint
The study endpoint was the recurrence of documented AF or of
symptoms suggestive of AF.
Figure 1. Anatomical reconstruction of left atrium in anteroposterior projection, with intended ablation lines superimposed (pale dots).
Dark red ring represents mitral annulus (MA); colored tubes represent pulmonary veins. Lines include a circular line isolating the pulmo-
nary veins (pulmonary line) and a line connecting the pulmonary line with the mitral annulus (PVMA). Inf indicates inferior; lat, lateral;
PV, pulmonary vein; sup, superior, and sept, septal.
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isolated segment to the mitral annulus to prevent surgically induced
LA flutter around the mitral valve; third, cryoablation of the right
atrial isthmus to prevent atrial flutter; and fourth, an LA appendec-
tomy to reduce the risk of stroke (Figure 1).
Surgical Procedure
The surgery was performed under cardiopulmonary bypass using
standard double-venous cannulation and aortic cross-clamping. The
LA was entered through the interatrial sulcus, and the incision was
extended superiorly and transversely toward the left superior pulmo-
nary vein and inferiorly and transversely toward the left inferior
pulmonary vein. A series of overlapping applications of a cryoprobe
15 mm in diameter, cooled at !60°C for 2 minutes was used
(Frigitronics) to join the ends of the atrial incision while encircling
the left pulmonary veins along the left edge of the left pulmonary
vestibule. A further 2 to 3 overlapping applications connected this
line to the mitral annulus.
Cryoablation of the right atrial isthmus was carried out via a small
right atriotomy over the acute margin using 2 or 3 applications of the
cryoprobe. LA appendectomy was then carried out by ligation of the
appendage at its base, resection of the appendage, and oversewing of
the incision. Cardiac biopsies were obtained from the right atrial wall
and the LA wall, from the LA appendage after resection, and from
each ventricle by use of needle biopsies. Tissue samples were
immediately fixed and sent for pathological examination. The tissue
was divided and fixed in 100% formalin for light-microscopic
examination and glutaraldehyde for electron microscopy. Before
closing, 3 pairs of temporary pacing wires (Streamline temporary
myocardial wires, Medtronic Inc) were attached to the heart: over the
right atrium (nonexcluded segment), over the LA posterior wall
(excluded segment), and over the right ventricle.
Postoperative Electrophysiology Study
An EP study was performed after surgery using the epicardial
electrodes in all patients. The spontaneous rhythm in each segment
was recorded with a bipolar pair (filtered at 30 to 400 Hz), and the
efficacy of isolation was tested by pacing the right atrium and the
isolated LA-PVR electrodes. Isolation of the LA-PVR was verified
by the presence of bidirectional block between the isolated segment
and the remaining atrial region (RAR). The ability to induce
sustained AF ("5 minutes) was tested in both the isolated PVR and
the RAR by extrastimulus pacing at cycle lengths of 600 and 400 ms
with up to 3 extrastimuli and by burst pacing to a cycle length of 200
ms. The data were recorded on a Quinton EPS or Prucka 4.0 EPS
systems and analyzed offline by 2 independent observers.
All patients were discharged in sinus rhythm without antiarrhyth-
mic agents or DC cardioversion. Patients were followed up clinically
and by serial ECGs to document the persistence of sinus rhythm.
Patients were asked to report any symptoms suggestive of recurrent
AF and to obtain an ECG if symptoms occurred. All patients were
contacted by telephone at the time of this report.
Results
Surgery was performed successfully in all patients. Patient
characteristics are shown in Table 1. The mean cardiopulmo-
nary bypass duration was 93#20 minutes (range, 74 to 144
minutes), with a mean aortic cross-clamp time of 62#18
minutes (range, 50 to 110 minutes). Preoperative coronary
angiography was performed in all patients. Two patients
(patients 3 and 6) had clinically unsuspected significant
coronary artery disease detected that required coronary artery
bypass grafting at the time of AF surgery. There were no deaths
Figure 1. Illustration of surgical procedure. Using a combination
of incision and cryoablation, PVR is isolated. LA appendage is
ligated (not shown). A tricuspid annulus–inferior vena cava line is
also produced by cryoablation. CS indicates coronary sinus.
TABLE 1. Summary of Patient Characteristics
Patient Age, y Sex
AF History, y
LA Size
Previous EP
Study or
Ablation
Repeat
Study
Isolated PVR
RhythmParoxysmal Persistent
1 53 M 5 2 3.4 No Yes (atrial flutter) AF
2 59 F 10 Nil 4.1 No No
3 55 M 1.5 Nil 4.1 No No
4 40 M 4 Nil 3.8 EP, no abl No
5 40 M 5 Nil 4.1 No Yes (AF)
6 49 M 5 Nil 4.0 EP, no abl No AF
7 53 M 3 3 4.0 EP, no abl No AF induced
8 59 F 11 Nil 4.0 No No
9 48 M 3 6 4.1 EP, no abl No AF
10 52 M 3 Nil 3.9 EP, no abl No
11 48 M 4 Nil 4.0 No No
12 60 M 9 Nil 4.3 Yes (PV) No AF
13 56 M 2 Nil 4.0 No No
14 42 M 1 Nil 3.9 No No
Mean 51#6.8 12 M 5.5#3.2 3 pts 4.0#0.2 6 pts 2 pts 5 AF
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Figure 1-5. 3D anatomic l m p of the LA showing the i tended ablation sit s (white 
dots). Reproduced from Ernst et al. with permission.102 
Figure 1-6. Showing the lesion set delivered by Todd et al. The incision 
circumventing the left atrium is shown together with the sites of cyro ablation to 
complete the electrical isolation of the posterior wall. Reproduced from Todd et al. 
with permission.103 
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More recently, Thomas et al. described the feasibility of AF ablation using a pattern similar 
to that by Todd et al using catheter technology only.104 A study comparing this lesion pattern 
to ‘standard’ WACA showed that the single ring patients had significantly fewer recurrences 
of AF compared at 2 year follow-up.105 However, when including all atrial arrhythmia, there 
was no significant difference between the 2 strategies.  
The same group have also reported on the arrhythmia mechanism in recurrent cases.106 In a 
series of 100 consecutive patients who underwent single ring ablation (66% PAF), 34 went 
on to a redo procedure. All patients who suffered a recurrence of AF had gaps in their 
ablation ring. Conversely, recurrences of AFl were found to be due to either peri-mitral 
circuits or through 2 gaps in the PW ring.  
1.3.7.1 Surgical AF Ablation 
There are a variety of techniques that can be applied in the open or closed chest for the 
surgical management of AF.107 The lesion patterns are variable depending on the device 
used.  
A bipolar clamp can be used in the open chest. This clamp is applied to the epicardial surface 
of the atrium near each pair of PVs. The clamp action is used to compress the atrial tissue 
onto the surface of the tool and bipolar RF energy is delivered. This tool causes both tissue 
damage from the crush effect but more importantly, there is excellent energy delivery to the 
tissue increasing the chance of a thorough, transmural lesion being delivered (Figure 1-7 A). 
Another such technique is to deliver a single-ring lesion set from the epicardial surface of the 
heart via a minimally invasive thoracoscopic port. This has become known as the ‘box-set’ 
pattern. In chapter 2, the reader will be introduced to more about the role of AF ablation 
during concomitant cardiac surgery and will be presented with the long-term outcomes from 
a single centre experience in over 100 patients using a form of this ablation. A newer 
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generation designed to deliver this lesion set is called the Cobra device. It is inserted into the 
chest 53 minimally invasive Ports. It uses a suction property to enhance the device’s 
adherence to the epicardial surface of the atrium to help ensure transmurality (Figure 1-7 B) 
 A third novel surgical ablation tool is called nContact.  It is applied to the posterior wall of 
the left atrium via a sub diaphragmatic approach. It can be used both to deliver lesions to the 
posterior wall and other linear lesions such as a mitral isthmus line. Complete posterior wall 
‘blanking’ can be achieved where not only is the posterior wall isolated in a box fashion, but 
it is completely ablated in its entirety. This reduces the potential issue of lesion recovery 
(Figure 1-7 C). 
 
 
 
 
Figure 1-7 has been removed due to Copyright restrictions.  
 
 
 
 
Figure 1-7. (A) The bipolar clamp used to deliver bilateral PV antrial isolation. (B) The 
Cobra device, delivered thoracoscopically to deliver a single ring lesion in a box pattern 
and (C) the nContact tool which is delivered via the sub diaphragmatic approach to 
deliver sequential linear lesions across the posterior wall (D). 
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1.3.7.2 Hybrid Ablation Strategies  
The series published by Lim et al.106 suggests that early cases of AF recurrence were 
exclusively due to failure in the adequacy of delivery of the box-set lesion. One possible way 
to deliver a more durable lesion is to perform both epicardial and endocardial ablation in an 
attempt to ensure transmurality of the lesion. There have been several commercially 
available devices designed to deliver this epicardial lesion pattern; one such, Epicor (St. Jude 
Medical, UK) is discussed in chapter 2.  
Atricure, a company who develop novel cardiac systems, have developed a tool which can 
deliver radiofrequency energy in a box-set pattern on the beating heart via 3 minimally 
invasive thoracoscopic ports. It has suction properties which help maintain good contact 
between the device and the epicardial surface, reportedly enhancing the integrity of the 
lesion delivered. Groups have been using this device in combination with catheter ablation to 
deliver the box-set pattern. The catheter procedure has been performed either at the same 
sitting or as part of a staged procedure with a 2 – 3 month interval. The aim is to deliver the 
epicardial energy first and then map and ablate the gaps via the catheter approach. It is 
therefore argued that an interval of 2 – 3 months is preferable, as this will allow for any 
oedema, which may mask incomplete block, to subside.  
The group led by Munneretto have led the way in this technique. Their published outcomes 
from a hybrid strategy, using implantable loop recorders to monitor arrhythmia recurrence, 
show a freedom from AF rate of 88% at mean follow-up of 28 months (where 25% of the 
entire group were on an AAD). Five of the 24 patients included in this series required 
additional catheter ablation at the second stage of the procedure, but the paper does not 
report the rhythm at time of arrival in catheter laboratory.      
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One potential key to long term success in PsAF ablation is, in the author’s opinion, the 
development of an effective and readily replicable generic lesion-set that improves on 
current models and does not rely on the complexities of tailored strategies.  
There are very limited cases reported in the literature of isolated LA posterior wall in patients 
with recurrences of AF. It can thus be hypothesised that:  
• Posterior wall isolation is an appropriate lesion set for the ablative management 
of AF 
• Cases of recurrence are predominately due to failures in technology to deliver 
durable isolation. 
1.4 Thesis Outline 
1.4.1 Aims 
The general aim of this research was to characterise the suitability of posterior wall isolation 
for the ablative management of AF.  
The specific objectives were: 
• To investigate the outcome from concomitant epicardial AF ablation at very 
long-term follow-up. 
• To gain an understanding of the difference in the electrical properties of the PW 
in patients who have historically undergone box-set epicardial ablation in those 
with freedom from and those with on going AF. 
• To investigate the relationship between BMI and LA pressure in an AF ablation 
population. 
• To investigate the long-term outcome from a novel procedure designed on the 
box-set concept using catheter ablation only. 
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1.4.2 Overview of The Upcoming Chapters  
• Chapter 2 will report a single centre experience of surgical AF ablation performed 
on a cohort of 110 patients, the majority during concomitant open chest surgery. This 
chapter describes the patient mix and provides an analysis of the very-late freedom 
from AF rates measured by 7-day ambulatory ECG monitoring. 
• Chapter 3 will describe to the reader the electrical properties of the PW in patients 
who underwent historical epicardial AF ablation. A total of 17 patients are included, 
6 of who had excellent outcomes from their original ablation procedure and no 
further AF at a minimum of 52 months.  
• Chapter 4 explores the possible mechanism of action between BMI and AF burden 
by investigating the relationship between BMI and LA pressure.  
• Chapter 5 introduces the reader to duty-cycled radiofrequency ablation. The 
outcome from a novel ablation strategy based on the box-set concept will be 
reported.  
• Chapter 6 provides a final discussion and conclusion, summarises the limitations of 
the studies and suggests areas for future development. 
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2 LATE OUTCOME OF HIGH INTENSITY FOCUSED 
ULTRASOUND EPICARDIAL ABLATION 
2.1 Introduction 
Atrial fibrillation is associated with valvular and ischaemic heart disease and as such is 
commonly found in patients undergoing cardiac surgery.13 Preoperative AF is an 
independent risk factor for long-term survival in surgical bypass patients.108,109 In valvular 
heart disease patients, those in AF preoperatively are older, have more co-morbidities and 
poorer left ventricular function than those in NSR. Several small studies have shown survival 
benefits from being in NSR during valvular heart surgery though it remains unproven 
whether AF is an independent risk factor for late survival.110,111  
The ECS consensus expert statement on catheter and surgical ablation for AF supports the 
use of surgical ablation during concomitant cardiac surgery for patients with PAF, PsAF and 
LS PsAF.22 Over 40% of patients with a history of AF who undergo cardiac surgery are 
offered concomitant AF ablation.112  
Since the initial introduction of the Cox-Maze procedure over 20 years ago, there have been 
many developments in the surgical treatment of AF. Currently employed techniques range 
from the Cox-Maze IV cut-and-sew method to epicardial linear ablation lines delivered 
through a variety of energy sources. One such energy source is High Intensity Focussed 
Ultrasound (HIFU). This technology is designed to deliver PV and posterior left atrial wall 
isolation on the beating heart using an encircling ‘cinch’ and create left atrial lines using a 
hand held wand device. By encircling around the pulmonary ostia, it also ablates areas where 
ganglionic plexi commonly reside and where dense collections of complex fractionated atrial 
electrograms (CFAEs) are found.  
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In our centre, we have over 5 years historical experience in using the Epicor HIFU ablation 
system (St. Jude Medical, UK). Patients with PAF, PsAF and LS PsAF have been treated 
with this technology, predominantly during concomitant valvular and non-valvular cardiac 
surgery. 
Seven groups have reported outcome data from epicardial AF ablation using the Epicor 
system in a total of 483 patients summarised in Table 2-1.113–118 Twenty-four hour 
ambulatory ECGs have been used in the majority of these previous studies.   
Our aim is to assess the safety and efficacy of the Epicor system using 7-day ambulatory 
ECG monitoring post 2-year follow-up. We present complication rates and follow-up data 
on our group of patients, with attention to the incidence of AF documented by 7-day 
ambulatory ECG or pacemaker interrogation. 
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Table 2-1. Summary of previously published series reporting on AF ablation during concomitant cardiac surgery using HIFU (AVR = aortic valve 
replacement, CABG = coronary artery bypass graft, LS PsAF = long standing persistent atrial fibrillation MI = myocardial infarction, NSR = normal 
sinus rhythm, PAF = paroxysmal atrial fibrillation, PsAF = persistent atrial fibrillation). 
Study Number Event monitor 
type 
Male gender 
n(%) 
Operation Type n(%) Patient numbers n(%)  	 NSR n(%) Device related 
complications PAF PsAF LS PsAF Time of F/U 
(months) 
PAF PsAF LS PsAF 
Ninet113 103 24 hour holter 59(58) MV surgery 46(44.6) 
2 valve surgery 22(21.3) 
AVR 17(16.5) 
CABG 7(6.8) 
Other 11(10.8) 
22(21) 5(5) 76(74) 6 100% 80% Nil reported 
Groh114 129 24 hour holter 79(61) MV surgery 65(50) 
2 valve surgery 35(28) 
CABG (41(32) 
AVR 20(16) 
Other 3 (2) 
43(33) 20(16) 66(51) 6 
12 
60(77) 
21(90) 
39(92) 
34(82) 
Nil reported 
Schopka115 110 24 hour holter 66(60) AVR 30(27) 
MV surgery 13(11) 
CABG 37(33) 
2 valve surgery 12(10) 
Other 30(27) 
(29) (31) (40) 12 (100) (58) (44) Nil reported 
Feyrer116 103 24 hour holter 
(at 3 and 6 
month) 
Not reported MV surgery 23(22.5) 
AV surgery (42(41) 
CABG 11(11) 
Other 5(5) 
37(36) 5(5) 55(53) 6 
12 
48 
(84) 
(77) 
(90) 
Not 
reported 
(50) 
(46) 
(40) 
Nil reported 
McCarthy117 24 30 day (at 6 
months) 
20(83.3) MV surgery 5(20.8) 
AVR 0(0) 
CABG 5(20.8) 
Other 1(4.2) 
2(8.3) 
 
4(16.7) 
 
18(75) 22 10(35.8) Nil reported 
Mitnovetski118  14 24 hour holter 12(86) MV surgery 3(21) 
AVR 4(29) 
CABG 9(64) 
4(29) 10(71) 9 4(29) 9(64) Nil reported 
Garcia119 30 15 day external 
loop 
21(71) AVR 15(50) 
MV surgery 3(10) 
CABG 10(33) 
Other 9(30) 
4(47) 16(53) 6 5(56) 7(44) Nil reported 
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2.2 Methods 
2.2.1 The Patients 
All patients who underwent an ablation using the Epicor device between the dates of January 
2006 and December 2009 were asked to participate in this retrospective study. All patients 
irrespective of AF classification or LA size were included. Institutional research & 
development and regional ethics approval was obtained.  
A total of 110 patients received an ablation: 76 male and 32 female. The mean patient age 
was 70. Preoperative AF classification was: PAF 29 (26%), PsAF 37 (34%) and LS PsAF 44 
(40%). Forty-eight patients underwent coronary artery bypass grafting, 70 had valve surgery 
(25 aortic valve replacement, 25 mitral valve replacements, 17 mitral valve repairs and 3 had 
double valve replacement) and 8 underwent lone epicardial ablation (2 PAF, 3 PsAF and 3 
LSPsAF).  
2.2.2 Study Design and Investigations 
Ninety-three patients retrospectively underwent either a 7-day period of monitoring or 
pacemaker interrogation, baseline demographics are shown in Table 2-2.   
The primary endpoint was the incidence of AF or AFl at >2-year follow-up as assessed by 
either a 7-day ambulatory ECG or permanent pacemaker interrogation.  The secondary 
endpoint was the complication rate. Baseline patient demographics including age, sex, 
NHYA functional class, CHA2DS2-VASc score, LVEF, LA diameter (as assessed by long 
axis parasternal view on transthoracic echo) and history of hypertension, diabetes, renal and 
pulmonary disease or previous stroke were recorded. The duration of preoperative PsAF was 
determined by a review of all available previous electrocardiograms (ECGs). Any episode of 
atrial arrhythmia lasting >30 seconds was recorded as a recurrence.22 120 
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Table 2-2. Baseline demographics of the surgical AF ablation population. (AVR = aortic 
valve replacement, BMI = body mass index, CABG = coronary artery bypass graft, 
CCF = congestive cardiac failure, CCS = Canadian Cardiac Society, COPD = chronic 
obstructive pulmonary disorder, CVE = cerebrovascular event, LA = left atrium, LS 
PsAF = long standing persistent atrial fibrillation, LVEF = left ventricular ejection 
fraction, MI = myocardial infarction, MVR = mitral valve replacement, NYHA = New 
York Heart Association, PAF = paroxysmal atrial fibrillation, PsAF = persistent atrial 
fibrillation). *Data expressed as median and (Inter Quartile Range) for non-normally 
distributed data. 
 PAF PsAF LS PsAF p value 
Number 26 34 33  
Age (years) 67.8(9.1) 69.8(11) 70.2(6.8) 0.08 
Male (%) 70 74 75  
Diabetic (%) 11.5 5.9 9.1 0.75 
CCS (0,I,II,III,IV) 12,1,8,4,1 21,0,11,1,0 15,3,9,5,0 0.26 
Previous CVE (%) 3.8 5.9 9.1 0.69 
CCF history (%) 3.8 17.6 6.1 0.13 
Prev MI (%) 7.7 5.9 3 0.74 
Hypertension (%) 65 73.5 48.5 0.10 
COPD (%) 3.8 0 3.0 0.55 
Renal disease (%) 0 2.9 0 0.41 
Cholesterol (%) 55.7 35 33.3 0.15 
Smoking history (%) 46 47 42.4 0.98 
LVEF (>50%, 30-50%, 
<30%) 77,15,8 82,15,3 88,6,6 0.68 
LA diameter (cm) 4.1(0.5) 4.6(0.6) 4.8(0.9) 0.01 
NYHA (mean) 2.1 2.3 2.2 0.39 
Pre-Op  CHA2DS2-VASc 1.5(1.0) 1.8(1.0) 1.6(0.9) 0.57 
BMI (kg/m2) 28(5.7) 27.1(4.8) 28.6(4.8) 0.73 
Crossclamp time (mins) 46(22.1) 50.4(25.8) 55.0(29.3) 0.67 
CABG (%) 46 41 30 0.50 
AVR (%) 46 9 33 0.01 
MVR (%) 19 53 58 0.05 
Standalone AF ablation 
(%) 2 3 3 0.98 
Follow-up (months)* 29(29) 25(12) 33(27) 0.54 
   
39 
 
Figure 2-1. Circos plot representing the surgical HIFU ablation cohort.120 This circular 
plot shows the relationship between the class of pre-operative AF and specified 
baseline characteristics. The size of each arc represents group size and the ribbons 
illustrate relationship size between groups. (AVR = Aortic valve replacement, CABG = 
Coronary artery bypass graft, CCF = Congestive cardiac failure, Chol = 
Hypercholesterolaemia, CKD = Chronic kidney disease, COPD = Congestive 
obstructive pulmonary disease, CVE = Cerebrovascular event, DM = Diabetes mellitus, 
HTN = Hypertension, LSPsAF = Long-standing persistent atrial fibrillation, LVmild = 
Normal or mild left ventricular systolic impairment, LVmod = moderate left ventricular 
systolic impairment, LVsev = severe left ventricular systolic impairment, MVR = Mitral 
valve repair/replacement, NYHA = New York Heart Association, PAF = Paroxysmal 
atrial fibrillation, PsAF = Persistent atrial fibrillation). 
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2.2.3 Surgical Procedure 
The surgical ablation technique performed was as previously described.115 In all cases, the 
Epicor positioning and sizing system was used. This was passed behind the SVC through the 
transverse and oblique sinuses and under the IVC. Once sized, the Epicor device was placed 
in order to create the box-set lesion. HIFU ablation energy was delivered using the 
UltraCinch device circumferentially around the pulmonary veins on the beating heart before 
initiation of cardiopulmonary bypass. In all cases a mitral isthmus line was performed using 
the wand. Acute block was not routinely assessed.  
2.2.4 Postoperative Management 
All patients received an antiarrhythmic agent (either amiodarone or sotalol) postoperatively 
for 3 months, along with warfarin, with a target INR of between 2 and 3. The duration of 
anticoagulation was guided by the individual risk factor profile (based on the CHA2DS2-
VASc score). Typically, for those patients without a secondary indication for 
anticoagulation, warfarin was stopped if the score was 0 (or 1 when the only point was for 
female sex). Patients were reviewed in the outpatient clinic at 3-monthly intervals with 
standard 12-lead ECG and physical examination.  
As part of this retrospective study protocol, a 7-day ambulatory ECG was performed at an 
interval greater than two-year post procedure. During the blanking period, some patients 
underwent an electrical cardioversion in an attempt to restore NSR. AF was defined as a 
period of continuous irregular atrial rhythm on a full disclosure ambulatory holter or 
permanent pacemaker interrogation lasting greater than 30 seconds.22 Any atrial arrhythmia 
reported outside of the study period was recorded as an arrhythmia recurrence.  
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2.2.5 Statistical Analysis 
Continuous variables are expressed as mean ± SD or median and IQR and were compared 
by one-way analysis of variance. Post hoc analyses were performed with the Tukey test. 
Categorical variables were compared by chi-square analysis. BMI and LA diameter were 
analysed as continuous variables, EF was treated as categorical data. Both univariate and 
multivariate logistic regression analysis was performed to determine the independent 
predictors of recurrent AF following ablation. A p value of <0.05 indicated statistical 
significance. All analysis was performed using SPSS version 20.  
2.3 Results 
There were no statistically significant differences between the three groups at baseline except 
for LA diameter which was significantly larger in the LS PsAF group. There were 
significantly fewer patients undergoing AVR in the PsAF group compared to the other two 
groups. There were no procedural complications or deaths directly related to the ablation 
procedure. Of the 110 patients treated with HIFU, there were 7 deaths in the follow up 
period with an in-hospital mortality of 1.8% (n=2) - 4 from post-operative complications 
unrelated to the AF ablation procedure or use of the Epicor device, 1 died from malignant 
disease, 1 a traumatic intracerebral bleed and 1 from end-stage heart failure. Patient numbers 
are illustrated in the CONSORT diagram in Figure 2-2. 
Of the 103 surviving patients, 90% (n=93) underwent 7-day ambulatory ECG monitoring 
greater than 1-year post procedure (median 27 months). For those patients with a permanent 
pacing system capable of reporting AF burden, this was used instead of a holter (3 patients, 2 
confirmed 100% AF and 1 NSR, none of these patients were monitored externally).  
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The overall results demonstrated that 49% of the patients (n=46) were in sinus rhythm, 1% 
(n=1) was in an atrial tachycardia, 9% (n=8) were in atrial flutter and 40% (n=38) had 
evidence of AF. Of the patients in NSR with no evidence of AF recurrence, five were taking 
an antiarrhythmic drug (AAD) at the time of monitoring (2 on amiodarone, 2 on sotalol and 
1 on flecanide). Four patients with evidence of on going AF were on an AAD (1 on 
amiodarone and 3 on sotalol).  
Figure 2-2. CONSORT diagram showing the flow of patients through the study period 
(LS PsAF = long standing persistent atrial fibrillation, n = number, PAF = paroxysmal 
atrial fibrillation, PsAF = persistent atrial fibrillation). Reproduced from Davies et al. with 
permission.132 
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2.3.1 Paroxysmal AF 
Of the surviving patients who underwent monitoring, 26 patients had PAF prior to ablation 
procedure. At >2 year follow up (median 29 months), 81% (21) were demonstrated to be in 
sinus rhythm on 7-day ambulatory ECG or pacemaker interrogation.  The mean LA diameter 
was 4.1cm and only 11% had any LV impairment. Sixty-five percent were hypertensive, 
12% were diabetic and 4% (n=1) had a history of previous cerebrovascular event. The 
average preoperative CHA2DS2-VASc score was 1.5. Of those patients with arrhythmia 
recurrence, the median number of episodes of AF seen on 7-day holter was 2 and the mean 
AF burden over 7 days was 78 minutes (SD 61).  
2.3.2 Persistent AF 
There were 34 surviving patients classified as having PsAF prior to the ablation procedure. 
At >2-year follow up (median 25 months), 56% had no evidence of AF recurrence on 
monitoring. The mean LA diameter was 4.6cm, 18% had previous admissions with 
congestive heart failure, 74% were hypertensive, 6% were diabetic and 3.6% had prior 
history of cerebrovascular event. The average preoperative CHA2DS2-VASc score was 1.8. 
Only 3 patients with previous PsAF had PAF in the post-operative period. In these 3 
patients, the median number of arrhythmic episodes was 4 (mean 7-day arrhythmia burden 
was 26 hours (SD 14). 
2.3.3 Longstanding Persistent AF 
Of the 44 patients who underwent ablation for LS PsAF, 33 surviving patients underwent 
monitoring at >2 year (median 31 months). Only 18% had no evidence of AF recurrence, 
65% were in PsAF and 12% were in a persistent atrial flutter (proven to be a left atrial flutter 
in 2 patients at subsequent electrophysiological study).  The mean LA diameter was 4.8cm. 
Forty-nine percent of patients were hypertensive, 9% had diabetes and 14% had a history of 
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previous cerebrovascular events. The average CHA2DS2-VASc score was 1.6. Twenty-two 
percent of patients were assessed to have a degree of LV impairment prior to surgery.  
Of the patients with recurrence of AF noted on the 7-day holters, 9 (11%) had episodes 
limited to 1 or 2 of the 7 days. 89% of patients had either normal sinus rhythm or AF 
throughout their 7-day holter. 
Regression analysis was performed to determine factors predicting AF recurrence. All 
variables were initially tested using univariate analysis. Those with a significance of p<0.2 
were then tested in a multivariate binary logistic regression model (Table 2-3). AF grade 
(OR 4.43 (95% CI 2.29-8.58, p<0.0009)), and LA size (OR 2.8 (95% CI 1.38-5.7, p=0.004)) 
were significant determinates for AF recurrence. BMI was not a significant determinant 
under univariate analysis (OR 0.94 (95% CI 0.86-1.02, p=0.134)) but when corrected for LA 
size and AF grade, was found to be significant (OR 0.87 (95% CI 0.78-0.99)). The possible 
mechanisms by which BMI exerts an effect on AF ablation procedures are discussed in 
chapter 4. 
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Table 2-3. Binary logistic regression showing impact of baseline variables on success 
rate of surgical ablation. (AVR = aortic valve replacement, BMI = body mass index, 
CABG = coronary artery bypass graft, CCF = congestive cardiac failure, CVE = 
cerebrovascular event, DM = diabetes mellitus, EF = left ventricular ejection fraction, 
LA = left atrial, MI = myocardial infarction, MV = mitral valve surgery) 
 Univariate Analysis Multivariate Analysis 
Variable Sig OR 95% CI         Sig       OR 95% CI 
AF Grade 0.000 4.43 2.29-8.58 0.001 3.988 1.74-9.10 
Sex  0.767 0.87 0.35-2.18    
Age 0.213 1.04 0.99-1.09    
CCF history 0.676 0.74 0.19-2.97    
MI history 0.613 0.62 0.10-3.91    
DM 0.949 0.95 0.22-4.07    
Hypertension 0.873 1.07 0.46-2.50    
Smoker 0.848 0.92 0.41-2.10    
CVE 0.956 0.96 0.18-5.00    
EF >50% 0.906 0.83 0.04-19.99    
EF 30-50% 0.217 0.21 0.02-2.52    
EF <30% 0.875 0.90 0.25-3.22    
AVR 0.767 1.15 0.46-2.88    
MV 0.063 0.44 0.18-1.05    
CABG 0.468 0.74 0.33-1.67    
Standalone 0.483 1.71 0.38-7.60    
BMI (kgm-2) 0.134 0.94 0.86-1.02 0.036 0.87 0.78-0.99 
Crossclamp time 0.184 1.01 0.99-1.10    
LA Size (cm) 0.004 2.80 1.38-5.70 0.030 2.70 1.10-6.63 
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2.3.4 Additional Interventions 
Four patients required permanent pacemaker implantation in the postoperative period (2 
patients with CABG, one with AVR and one with AVR plus grafts). 6 patients were 
cardioverted in the index admission. One patient (lone surgical AF ablation) underwent late 
catheter ablation. The ablation line was not intact at the time of EP study and further 
endocardial ablation in an attempt to achieve posterior wall isolation was unsuccessful in 
maintaining sinus rhythm.   
2.4 Discussion 
This is the first report of patients undergoing epicardial AF ablation with HIFU with a late 
follow-up by extended ambulatory monitoring using either a 7-day ambulatory ECG or 
permanent pacemaker interrogation. Previous groups have reported the recurrence rate of AF 
post HIFU AF ablation (Table 2-1). Ninet et al.113 reports an overall freedom rate of 85% at 
6 months as determined by 24-hour ambulatory ECG monitoring with over 70% of their 
patient cohort being as described as having permanent AF. They report a 100% sinus rate at 
6 months in the combined group of preoperative PAF/PsAF and 80% in those with 
permanent AF.  
Groh et al.114 report outcomes between two classes (a combination of PAF/PsAF and 
permanent AF) at 6 and 12 months.  A significant loss to follow up at 12 months is seen 
including only 64 of the initial 129 enrolled patients (119 at 6 months). Of the total patients 
included in follow up, the percentage of patients in NSR are 83%/84% and 86% at 6/12 and 
18 months respectively with better results seen in the PAF group (92% vs. 77% at 6 months).  
More recently, Feyrer et al. reported on the long term outcomes from a similar population, 
90% of PAF and 40% of permanent AF maintaining sinus rhythm at 48 months.116 However, 
24 hour holter monitoring was only used at the 3 and 6 month follow up point and for the 
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late follow up of 4 years, only 30 patients were included with no clear monitoring 
uniformity.  A significant proportion of their patients were on maintenance AADs or 
betablockers.  
An interesting study by McCarthy et al. describe the outcomes of 24 HIFU ablation cases.117 
Nine (37%) of these patients who had recurrence of AF underwent an electrophysiological 
study with view to further ablation. They found absence of intact ablation line in all 9 
patients, i.e. it is possible that AF recurrence was due to the inadequacy of the technology to 
delivery durable lesions.   
The study by Garcia et al. gives broadly similar outcome rates after the initial ablation using 
the Epicor device.119 They go on to provide a description of their patient cohort who 
underwent an electrophysiological study at 6-months. They found an isolated PW in 38% of 
cases. They studied 16 patients with successful outcome (i.e. no further atrial arrhythmia) 
from the initial HIFU ablation and found intact PW isolation in only 4 of them. 
Unfortunately, the study fails to report the percentage of patients with on going AF in who 
the PW was isolated. They also do not offer any insight into the conduction times into and 
out of the box region in either outcome group.  
Our results have shown that although freedom from AF can be achieved in over 80% of 
patients with PAF, in patients with LS PsAF, only 18% have successfully maintained sinus 
rhythm at >2 year follow up. This contrast to previously published data may in part be 
explained by our extended monitoring period. Edgerton et al. has demonstrated that the 
reported incidence of AF following surgical ablation is significantly higher when 24-hour 
holter monitoring is extended to 7-days,121 and suggested that this is the routine monitoring 
period following surgical ablation. Our results show that 11% of patients in whom AF was 
detected may have been misdiagnosed had monitoring been limited to 24 hours.  
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Another possible explanation for the inferior results seen in our study is the length of follow-
up period compared to most outcome series. A natural attrition rate is seen in studies 
following up AF ablation patients; our median follow-up was 29 months, significantly 
greater that the majority of previously published data.  
There are many possible explanations for the failure to restore NSR in our case series. It is 
possible that HIFU has not resulted in electrical isolation, or that complete isolation of the 
posterior wall of the LA is an insufficient lesion set to restore sinus rhythm. Alternatively, it 
may be that the success Epicor enjoys is not through PWI but through another process such 
as GP modification or substrate debulking. McCarthy’s finding that all patient who 
underwent late electrophysiological study for AF recurrence had incomplete ablation lines 
however supports the first explanation. However, without post HIFU ablation invasive EP 
study data, this issue will remain speculative.     
We saw that the outcome of freedom form atrial arrhythmia is dependent on BMI, AF class 
in the pre-operative period and the LA size. It has long been established in many case series 
and randomised controlled trials that the LA size is of prognostic relevance with regards to 
the outcome from an AF ablation procedure.122,123 Possible mechanisms behind this link are 
discussed in section 1.2.6.2.2 but include processes such as left atrial fibrosis leading to 
anatomical and electrical  remodelling.  
The association between BMI and AF is also well documented, as is the strength of a raised 
BMI as a poor prognostic marker following an ablation procedure. Perhaps the best study 
investigating this association is the Legacy Study.124 This investigated the effect that 
reducing BMI has on AF burden. It found that in patients with a BMI of 27 or greater, a 9% 
reduction in BMI lead to a six-fold decrease in AF.  Proposed mechanisms of action include 
a decrease in hypertension driven afterload, reduction in inflammatory responses, a decrease 
in pericardial fat and prevalence of diabetes.  One of the possible mechanisms of action 
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through which a raised BMI influences AF is through an increase in the mean LA pressure. 
We investigated this association in chapter 4, but failed to demonstrate any clinically 
meaningful correlation. 
2.4.1 HIFU and Alternative Epicardial Energy Sources 
HIFU is an energy source that focuses the ultrasound up to a depth of 1cm. It has the 
theoretical advantage in that it can be used on the beating heart and can ablate over coronary 
arteries with minimal risk of compromise to the blood flow. However, the continual washing 
of the endocardium by blood at 37 degrees and the variable thickness of atria raises the 
possibility that transmural ablation line integrity cannot be assured. An Italian group have 
described the histopathological findings following LA surgical HIFU ablation in 2 cases.125 
In both, they found a complete transmural lesion with replacement of the muscle with a 
fibrous band at 6 and 48 months following ablation.  
Besides HIFU, there are several other ablation energy sources available. Radiofrequency 
(RF) ablation is commonly used during endocardial (catheter) ablation techniques but its use 
during concomitant surgical procedures gives the operator a method of delivering a 
continuous transmural lesion set in a rapid and safe setting. However, the PVs must be 
avoided at the risk of vein stenosis and there remains a possibility of intramural thrombus 
formation. Oesophageal and circumflex artery damage have been reported. Because of the 
way the energy is delivered, monopolar RF is not as reliable as HIFU in delivering a 
transmural lesion. Bipolar RF devices however show better medium term results, particularly 
in the persistent and long-standing groups.126 Bipolar energy can be delivered through a 
variety of different tools and patterns. These are discussed in depth in section 1.3.7.1. 
Probably the most prevalent in use today include the bipolar clamp which is based on the 
WACA lesion patters and the Estech Cobra and nContact which delivers patterns based on 
the box-set.   
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Cryoablation use helium to cool tissue to around -60°C, eventually resulting in inflammation 
and fibrosis without loss to stromal integrity.127 Although results appear similar to RF, 
cryoablation has certain advantages such as visual confirmation of the ablation integrity, a 
lower likelihood of causing intramural thrombus and its safety in relation to the pulmonary 
veins and circumflex artery.  
Microwave energy sources have shown poor outcomes though data is lacking. The heat-sink 
phenomenon resulting from poor tissue contact may result in incomplete ablation lines. 
Laser ablation uses high-energy optical beams to deliver transmural ablation lines, 
demonstrated in animal models, though like microwave, there is currently a lack of large-
scale human data.  
The 2012 consensus guidelines suggest that in patients with LS PsAF, a biatrial procedure 
should be considered.22 During the HIFU ablation in this series, no patients received ablation 
in the right atrium, another factor that perhaps explains why our results from LS PsAF 
patients were so poor.   
2.4.2 Study Limitations 
There are limitations to this study. Firstly, although 7-day ambulatory ECG monitoring is 
considered an acceptable compromise between accurate monitoring and patient 
inconvenience, it is still possible that periods of AF are going undetected. That said, the aim 
of AF ablation therapy should be primarily about symptom control and improving disease-
related quality of life. Recently, validated AF specific health related quality of life 
questionnaires have been developed. We would endorse calls for future AF ablation outcome 
studies to use this as a secondary outcome.  
We noted that the majority of surviving patients lost to follow up had LS PsAF. It is possible 
that this has resulted in a skew in the results. However, the outcome from the longstanding 
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group is such that it is unlikely to have had a significant impact in the overall conclusion of 
the study.  
The ESC guidelines22 recommend that PV exit and entry block are assessed at the time of 
surgical AF ablation; this was not routinely performed in our practise and could possibly 
have adversely influenced outcome.  
2.5 Conclusion 
We conclude that high intensity focussed ultrasound surgical ablation for AF using the 
Epicor system is a safe system. The class of AF prior to surgery, LA size and BMI determine 
the long-term outcome. Though we saw outcomes for PAF comparable to other ablation 
systems, the inferior results in the PsAF and LS PsAF groups lead us to suggest that 
alternative ablation strategies are considered. 
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3 THE LATE ELECTROPHYSIOLOGICAL CONSEQUENCES 
OF POSTERIOR WALL ISOLATION IN PATIENTS WITH 
ATRIAL FIBRILLATION  
3.1 Introduction 
The mechanism by which AF is initiated and sustained is complex and incompletely 
understood. It is clear that the majority of triggers for AF reside within the PVs but there are 
also influential non-pulmonary areas. Though triggers are especially important for PAF, in 
PsAF a number of different mechanistic theories have been proposed (section 1.2.6.3). 
Regardless of the mechanism underlying PsAF, some evidence suggests that the bulk of the 
substrate for these mechanisms resides in the PW of the LA.81,96,128   
Consistent with these different theories, a wide variety of different ablation techniques are 
currently being practiced across international centres.  The majority of operators rely on a 
stepwise approach involving PVI followed by further substrate modification. These 
techniques are sometimes personalised to the individual case.  
Alternative ablation techniques rely on the identification and successful ablation of CFAEs, 
ganglionic plexi (GP), or more novel techniques involved the mapping and ablation of 
putative rotors129 or areas of low voltage.96 These techniques are highly complex, time 
consuming and rely on the skill of the operator to be able to identify all appropriate 
electrophysiological targets.  
An entirely different strategy is to accept the assumption that the bulk of the substrate on 
which AF propagates resides within the posterior wall of the LA. Several groups are 
investigating the application of an empirical ablation strategy that results in posterior wall 
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isolation.119,130 There is evidence to suggest that such an end-point may be sufficient in 
maintaining sinus rhythm in the majority of patients without the complexities involved in 
other approaches.119,131  
Once patients have undergone ablation with the box-set, it is unclear whether a successful 
outcome results from extensive debulking of the LA muscle; GP alteration / destruction; PVI 
or from isolation of the entire PW and PV substrate.  
We wished to determine whether the success of the box-set pattern was due to complete 
electrical isolation of the PW. One possible model to investigate this was to study the group 
of patients who had previously undergone AF ablation using epicardial box-set lesions 
delivered using HIFU as described in chapter 2.132  
The aim of this study was to characterise the very-late electrical properties of patients in 
whom the ablation procedure had been a success and compare them to others with on-going 
AF. We sought to recruit 10 patients from each group for a diagnostic transseptal EP study. 
This study was performed in accordance with the Declaration of Helsinki and with the 
approval of the institutional research and development department and of the West of 
Scotland Regional Ethics Committee. This permission extended to the diagnostic study only; 
any subsequent ablation procedures were performed as ‘usual care’ with fully informed 
written consent being gained prior to the study.   
3.2 Methods 
3.2.1 The Patients 
101 patients who had previously undergone HIFU AF ablation greater than 4 years ago were 
screened for inclusion in the study (2 of the 103 patients described in chapter 2 died between 
completion of that study and commencement of this).132 Seventeen patients agreed to late EP 
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study, 11 with on going AF and 6 in NSR (Figure 3-1).  The studies were conducted at a 
mean of 65 months post-surgical ablation. Fourteen underwent HIFU concomitantly with 
cardiac surgery and 3 had surgical AF ablation for lone AF. One patient had a permanent 
pacemaker in situ (case 5, pre-operative infrequent PAF and in NSR post-operatively).  
3.2.2 Recruitment 
At routine follow up, patients were introduced to the study and invited to participate. Those 
who expressed an interest were given a patient information sheet (PIS) and were contacted 
by telephone to confirm willingness to participate 2-days later. NSR was confirmed by the 
absence of symptoms, a 7-day full disclosure ambulatory electrocardiogram (ECG) 
confirming absence of AF (and other atrial arrhythmia) and a 12-lead ECG at time of 
recruitment. The AF group contained those patients having any documented recurrence of 
AF following a 3-month blanking-period post surgical ablation. Patients with recurrences 
solely of AFl were included in the NSR group but described separately. The patient 
demographics (as at time of epicardial AF ablation) are shown in Table 3-1.  
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Figure 3-1. Flow diagram showing the journey through the post-operative 
electrophysiological study. (AF = Atrial fibrillation, F/U = Follow-up, HIFU = High 
intensity focussed ultrasound, n = Number, NSR = Normal sinus rhythm, PIS = 
Patient information sheet)  
 56 
Pa
rt
ic
ip
an
t 
N
um
be
r 
Pr
e-
op
 A
F 
ca
te
go
ry
 
Pr
e-
op
 A
F 
du
ra
tio
n 
(m
on
th
s)
 
Pr
e-
op
 
D
C
C
V
 
Pr
e-
op
 
A
A
D
 fa
ile
d 
O
pe
ra
tio
n 
O
p 
to
 E
P 
du
ra
tio
n 
(m
on
th
s)
 
LA
 si
ze
 
(A
P)
 / 
(c
m
) 
EF
 (%
) 
PP
M
 
N
TH
 
C
A
D
 
Po
st
-o
p 
rh
yt
hm
 
01 LSP 14 1 - CABG 60 4.0 20 - - Yes NSR 
02 LSP 36 0 - MVR 54 4.6 60 - - - NSR 
03 LSP 30 0 Flec MV Repair 96 5.2 70 - - - AF 
04 LSP 30 1 - AVR/MVR 82 2.8 60 - - - NSR 
05 PAF 24 0 - CABG 84 4.6 45 Yes Yes Yes PAF 
06 PsAF 6 1 - CABG/ AVR 52 3.8 45 - - Yes NSR 
07 LSP 50 0 Flec, Sot, Amio Lone 56 4.2 58 - - - NSR 
08 LSP 14 1 - MV Repair 70 5.3 52 - - - NSR 
09 PsAF 5 0 - CABG 63 5.1 35 - - Yes NSR 
10 LSP 15 1 Amio CABG 71 5.1 50 - Yes Yes AF 
11 LSP 60 1 - MV Repair 51 6.2 60 - Yes Yes AF 
12 LSP 54 1 - Lone 17 5.1 60 - - - AF 
13 LSP 10 0 - AVR 98 3.8 45 - - - NSR 
14 LSP 48 2 Amio Lone 13 5.4 30 - - - AF 
15 LSP 144 0 - MVR 83 5.2 55 - - - AF 
16 LSP 18 0 - MVR 60 3.8 60 - - - NSR 
17 LSP 24 3 Sot CABG 43 4.2 60 - Yes Yes NSR 
Table 3-1. Post-operative electrophysiological study participant demographics and operative data (AAD = Antiarrhythmic drug, Amio = Amiodarone, 
BMI = Body Mass Index, CAD = Coronary Artery Disease, CTI = Carvotricuspid Isthmus Ablation, CVE = Cerebrovascular Event, DCCV = DC 
Cardioversion,  Flec = Flecanide, LA = Left Atrial, AF = Atrial Fibrillation, AP = Anterioposterior, cm = centimetre, DM = Diabetes Mellitus,  EF = 
Ejection Fraction, HTN = Hypertension, LSP = Longstanding Persistent Atrial Fibrillation, PPM = Permanent Pacemaker, Pre-op = Preoperative, 
PsAF = Persistent Atrial Fibrillation, Sot = Sotalol) 
 57 
 
Table 3-2. Invasively assessed conduction times in milliseconds (ms) expressed as exit and entry between the pulmonary veins / posterior wall and 
coronary sinus. (AF = Atrial fibrillation, CFAE = Complex fractionated atrial electrogram, DCCV = Direct current cardioversion, EP = 
Electrophysiological, HIFU = High intensity focussed ultrasound, PV = Pulmonary veins, PW = Posterior wall, WACA = Wide area circumferential 
ablation). 
 LUPV LLPV RUPV RLPV PW Arrhythmia 
following 
HIFU 
Additional 
Ablation at 
EP study? 
Endocardial 
ablation 
strategy 
PWI 
achieved? 
Exit Entry Exit Entry Exit Entry Exit Entry Exit Entry 
01 192 194 200 190 160 166 166 172 190 226 AF No N/A N/A 
02 Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Flutter No N/A N/A 
03 80 128 No capture 54 152 126 106 132 108 106 AF Yes Linear ablation 
to PW 
No 
04 270 226 196 192 272 304 220 284 260 252 Flutter No N/A N/A 
05 102 92 No capture (no muscle) 176 118 No capture (no muscle) 98 98 NSR No N/A N/A 
06 Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked NSR No N/A N/A 
07 Rapid reversion to AF following DCCV – proceeded onto additional ablation AF Yes Bilateral WACA 
and roof line 
Yes 
08 No capture (no muscle) 136 104 AF Yes Roof and floor 
line  
Yes 
09 Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked NSR No N/A N/A 
10 Reversion to AF 118 106 Reversion to AF AF No N/A N/A 
11 Reversion to AF following PW testing 145 152 Reversion to AF 120 118 AF No N/A N/A 
12 Rapid reversion to AF following DCCV – proceeded onto additional ablation AF Yes Linear ablation 
to posterior wall. 
No 
13 Reversion to AF following PW testing – proceeded onto additional ablation 42 40 AF Yes Bilateral WACA  Yes 
14 Rapid reversion to AF following DCCV – proceeded onto additional ablation AF Yes Linear ablation 
to posterior wall 
No 
15 Unsuccessful DC Cardioversion – CFAE throughout PW and PVs AF No N/A N/A 
16 Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Blocked Flutter Yes Mitral isthmus N/A 
17 160 138 194 204 148 200 190 186 158 154 AF Yes Completion of 
box-set. 
No 
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3.2.3 The diagnostic study 
A transseptal EP study was performed in all patients. Patients with a CHA2DS2-VASc of >1 
and on-going atrial arrhythmia were anticoagulated with either warfarin (target INR 2.0-3.0) 
or dabigatran (150mg bd) for a minimum of 3 weeks prior to the study.133 All diagnostic 
studies were performed as a day-case using IV sedation (diazemuls and diamorphine titrated 
to response). Access was gained via the right femoral and subclavian/internal jugular vein. A 
decapolar catheter was placed in the coronary sinus (CS) and a quadripolar catheter in the 
right ventricle.  
Using a standard Brockenbrough needle, a transseptal puncture was performed to allow 
passage of a steerable sheath - Channel, (BARD Electrophysiology) or Agilis® (St. Jude 
Medical) into the LA. Puncture was facilitated using a combination of contrast injection and 
pressure monitoring. IV heparin was administered to maintain the ACT at >300s for the 
duration of LA instrumentation. Pulmonary venography was performed for all PVs. A 
circular mapping catheter (Expandable Lasso or AFocus II, St. Jude Medical) was 
sequentially placed in all four PVs and flat on the PW.  
For patients in NSR at the time of the study, we tested for exit and entry block and recorded 
the conduction times between CS and PV/PW. Those in AF at the time of the study were 
cardioverted (200J biphasic AP pad position) on a maximum of two occasions to allow 
conduction to be assessed.  
In selected cases of apparent PW isolation (defined as the absence of electrical activity, or 
evidence of spontaneous isolated atrial complexes), we tested for pace/detect within the PW. 
A passed a second catheter alongside the steerable sheath and used it alongside the mapping 
catheter to test for conduction contained within the isolated PW.  
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3.2.4 Additional ablation 
Further ablation was performed with 4mm irrigated-tip ablation catheters (Smarttouch; 
Biosense-Webster or TactiCath; St. Jude Medical) facilitated by the use of a steerable sheath 
(Agilis; St. Jude Medical). The standard ablation settings consisted of an upper temperature 
limit of 45°C, radiofrequency power of 25 to 40W, and a flow rate of 17 to 30 mL/min. 
Power delivery was reduced to 25W near the oesophagus. A voltage map was produced 
using either CARTO (Biosense-Webster) or NavX (St. Jude Medical). Additional ablation 
was performed in 7 patients with symptomatic drug refractory atrial arrhythmia: 5 cases for 
AF and 2 for AFl. Additional lesions were delivered either around the pulmonary vein ostia 
and/or LA roof and floor to complete the existing lines created by the HIFU procedure. The 
ablation goal was validated PWI in the cases of AF recurrence and termination of marco-
reentrant circuits in the case of flutter.  
3.3 Results 
3.3.1 Free from Atrial Fibrillation – NSR 
Of the six patients who had an absence of AF, only 3 were completely free from any atrial 
arrhythmia recurrence the remaining 3 had experienced episodes of documented AFl. Of the 
3 patients where no atrial arrhythmia had occurred since surgical ablation, two had originally 
experienced PsAF pre-operatively (cases 6&9) and the other infrequent PAF pre-operatively 
only (case 5).  
In cases 6&9, there was no conduction into or out of the PW during capture pacing from the 
CS together with isolated potentials throughout the PVs and the PW (Figure 3-2).  
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Figure 3-2(A). With the circular mapping catheter (PV) placed flat on the posterior wall, 
an isolated premature atrial beat is seen showing electrical isolation of this region 
during sinus rhythm. (B) Circular mapping catheter (PV) in the right upper pulmonary 
vein and capture pacing from the coronary sinus, there is no evidence of conduction 
into the vein. Also seen is a non-conducted pulmonary vein potential (case 9). 
 
A
B
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In the patient with prior pre-operative infrequent PAF (case 5), there was no evidence of 
either exit or entry block from the posterior region (Figure 3-3).  
 
 
Figure 3-3. In a patient with preoperative PAF and freedom from any recurrent atrial 
arrhythmia. Pacing from CS distal demonstrates intact conduction between the 
coronary sinus and the posterior wall with a conduction time of 78ms (case 5). 
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3.3.2 Free from Atrial Fibrillation – Atrial Flutter 
Of the 6 patients with freedom from AF, 3 have experienced documented recurrences of 
atypical paroxysmal atrial flutter. In 2 cases, the PW was found to be silent with intact block 
throughout the veins and posterior LA. The other one case had very delayed conduction 
between the PW and the CS (case 4). The area of conduction gap is identified near the RSPV 
(Figure 3-4). 
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Figure 3-4. In a patient with recurrence of paroxysmal left atrial flutter but freedom from 
atrial fibrillation. (A) Pacing from PV9-10 (on the posterior wall) to the CS has a 
conduction time of 230ms (B) whereas 6-7 to CS is 260ms. (C) Earliest signal from CS 
pacing is seen in 9-10. (D) Posterior-anterior fluoroscopy image showing the circular 
mapping catheter on the posterior wall. The lesion gap was localised to the left side of 
the roof line (case 4). 
 
C 
D 
A
C
B
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In one of the cases of post-operative AFl, the patients remained symptomatic and we 
proceeded on to ablate a peri-mitral flutter circuit (case 16, Figure 3-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. In a patient with mitral valve replacement, pre-operative longstanding 
persistent atrial fibrillation and on-going symptomatic paroxysms of an atypical atrial 
flutter. (A) NavX voltage map (bipolar peak to peak) illustrates the border of the scar 
delivered by the HIFU device and the electrically silent posterior wall. (B) Surface 
marking show density of recordings over the posterior wall. (C) A peri-mitral flutter was 
successfully entrained by pacing manoeuvres from the coronary sinus catheter and 
ablated back to sinus rhythm by joining the mitral annulus to the adjacent inferior 
border of the HIFU scar. Colour coding: <0.2 mV=scar (grey), 0.2 to 0.5 mV=altered 
atrial tissue (red, yellow), >0.5 mV=healthy atrial myocardium (purple)90 (case 16).  
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3.3.3 Atrial Fibrillation 
 
Figure 3-6. In a patient with aortic valve replacement, pre-operative long-standing 
persistent atrial fibrillation and on-going symptomatic paroxysms of atrial fibrillation. 
The circular mapping catheter is on the posterior wall. Capture pacing from the 
coronary sinus shows rapid conduction to the posterior wall around 40ms.    
 
We studied a total of eleven participants with AF following the ablation procedure. In all 
instances, persistent atrial electrograms were present throughout the PW and PVs, ranging 
from grade 1 to 5 in degree of fractionation.134 DCCV was performed to restore NSR and 
allow for the conduction between the CS and the PW/PV to be assessed; rapid reversion 
back to AF limited assessment in 7 patients (cases 7, 10-15). Where tested, the conduction 
times between the PW/PVs and the CS are shown in Table 3-2. There were no instances of 
conduction block or PW isolation in any of the persisting AF cases. 
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Figure 3-7. In a patient with previous coronary artery bypass grafting, pre-operative 
longstanding persistent atrial fibrillation and on-going persistent atrial fibrillation. The 
NavX voltage map (bipolar, peak to peak) shows minimal evidence of scar delivered by 
the HIFU apparatus and an electrically active posterior wall. The additional endocardial 
ablation points delivered to complete the box are shown as red dots and the CS 
catheter is shown in red. Colour coding: <0.2 mV=scar (grey), 0.2 to 0.5 mV=altered 
atrial tissue (red, yellow), >0.5 mV=healthy atrial myocardium (purple)90 (case 17). 
 
In summary, of the 11 patients with post-operative AF, none showed any evidence of PW 
isolation. Conversely, of the 6 patients with absence of post-operative AF, 4 had electrically 
isolated PW, one had delayed conduction between PW and CS and one (post-operative 
infrequent PAF only) had intact conduction.  
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3.3.4 Additional Findings During AF Ablation 
3.3.4.1 Example 1 (Case 13) 
Though in NSR at the start of the procedure, instrumentation of the LA initiated AF with 
organised grade 5 fractionated electrograms throughout the PW. Voltage mapping showed 
established transmural scar line along the left atrial roof and floor. We proceeded to isolate 
the right PV pair using a standard wide area circumferential ablation approach resulting in 
rhythm organization (cycle length of 250ms). Following completion of the left PV-encircling 
lesion set continuous with the roof-line, spontaneous resolution of SR occurred. The PW is 
shown to contain a marcoreentrant circuit while surface ECGs show NSR (Figure 3-8). This 
PW block persisted during the administration of 15mg of adenosine, sufficient to caused AV 
block. 
Figure 3-8. Following successful ablation back to sinus rhythm, the circular mapping 
catheter on the posterior wall demonstrates an enclosed circuit most likely an atypical 
macro-reentrant in the presence of normal sinus rhythm on the surface electrograms.  
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3.3.4.2 Example 2 (Case 7) 
DC cardioversion resulted in non-sustained sinus rhythm; no conduction intervals were 
obtained during this short window but the circular mapping catheter on the posterior wall 
showed fractionated signals. During AF, a voltage map was constructed using CARTO 
(Figure 3-10); established transmural scar is evident along the floor of the left atrium but was 
incomplete on the roof and anterior to both pairs of pulmonary veins. Spontaneous return of 
sinus rhythm resulted from bilateral PV-encircling lesions together with the completion of a 
roof-line (Figure 3-11).  
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Figure 3-9(A). Completion of the WACA lesion encircling the right-sided veins to join 
the roof line resulted in reversion to sinus rhythm. (B) Following completion of the 
bilateral PV-encircling lesions joining to the HIFU roof and floor lines, sinus rhythm is 
seen on the surface electrodes while the PW (here demonstrated through the ablation 
catheter, Map 1-2) shows the PW to persist in flutter (case 13). 
A 
B 
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Figure 3-10. CARTO voltage map prior to catheter ablation energy delivery (scale 0.01 to 2.3mV). The red depicts areas of low 
voltage (i.e. Scar) purple/blue are areas of relative high voltage. We view the posterior wall from the left posterior oblique view (A) 
and right posterior oblique (B). Clearly visible is the scar in red running across the floor of the left atrium which has been previously 
delivered by the Epicor apparatus.    
A B 
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Figure 3-11. CARTO voltage map and superimposed catheter ablation energy delivery 
markers, here depicted as pink dots (scale 0.01 to 2.3mV). Complete WACA lesion set 
encircling the right-sided pulmonary veins is viewed. On the left we see the ablation 
lesions running up the posterior aspect of the left pulmonary vein pair to join the scar 
previously delivered by Epicor (in red). The ablation catheter is seen here touching the 
middle of the posterior wall and suggests that there is an enclosed flutter circuit 
persisting in this region, where the surface ECG showed the patient to be in sinus 
rhythm (Figure 3-9 B).   
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3.3.5 Outcome from Additional Ablation Cases 
All cases in whom additional ablation was performed remain now in sinus rhythm at 
minimum of 6-month follow-up (one on a class 3 antiarrhythmic) except one (case 17) in 
whom the PW was not successfully isolated due to the patient poorly tolerating the catheter 
ablation procedure under conscious sedation. 
3.4 Discussion 
Although several groups have reported on the invasive electrophysiological findings 
following ablation,119,135 to the best of our knowledge, this is the first study aiming to 
describe the association between PW isolation and long-term (>4 years) freedom from AF. 
A summary of the previous knowledge gained from such studies is provided in Table 3-3, 
most of which is obtained from studies involving redo procedures. As such, there is a skew 
against reporting what constitutes a successful outcome.  
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Study Number Lesion pattern / 
Energy 
Validated 
PWI? 
Follow-up findings Conclusions Complications 
Catheter Based 
Ernst et al.102 
Case series 
13 RF; Box, MI 0%  100% AF recurrence but no prior PWI.  Failure to deliver intended lesion set resulted 
in 100% AF recurrence.  
 
Nil reported. 
Tamborero et al136 
RCT  
60: 35 PAF, 13 
PsAF and 12 LS 
PsAF 
RF; BiWACA, roof 
and floor line 
100% 67% of initial PWI group with recurrent 
arrhythmia had reconnected roof-line and 
electrical activity on PW.  
 
“LA posterior wall isolation does not improve 
the outcome of CPVA” 
1 TIA  
1 inf. STEMI. 
Kumagai et al137 91 PAF RF; Box 90% 6 redo cases (3 AFl/AT, 3 AF); all had 
reconnection – none had intact PWI 
“86 (95%) of the 91 patients were free of AF, 
including six patients after the second 
procedure without antiarrhythmic drugs. The 
remaining five patients were arrhythmia-free 
but required drugs.” 
 
Nil reported. 
Lim et al.106  
Case series 
100: 66 PAF, 18 
PsAF, 16 LS 
PsAF. 
RF; Box ± MI ± CTI  96% “30 of 34 patients had breaches in the 
single ring of lesions that led to resumption 
of electrical activity in the previously 
isolated PLA.” “… none of the 4 patients 
who still had intact isolation of the PLA 
had recurrence of AF after their first 
procedure…” 
 
“Recurrence of atrial arrhythmias after single-
ring isolation of the PLA and pulmonary 
veins is usually associated with reconnection 
across the ring of ablation lesions…” 
Nil reported. 
Sanders et al.138 
Case series 
27 “chronic” AF RF; BiWACA, roof 
and floor line, CTI 
Yes One case of PWI with AF recurrence. “Isolation of the posterior-LA in patients with 
chronic AF is associated with prolongation of 
the AFCL, incremental to the effect of PV 
isolation, and termination of AF in ≈20%.” 
 
1 tamponade  
1 temporary phrenic nerve 
injury. 
Chen et al.139 
Case series 
42: 18 PAF, 14 
PsAF and 10 LS 
PsAF 
 
 
 
 
 
 
BiWACA, roof and 
floor line 
100% 6 cases of redo for AF; all had reconnection 
of PW. 
“Silencing electrical activity in the PIA is 
feasible, and capable of decreasing the rate of 
AF recurrence.” 
 
Nil reported.  
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Study Number Lesion pattern / 
Energy 
Validated 
PWI? 
Follow-up findings Conclusions Complications 
Surgical based 
Todd et al.103 
Case series 
14; 11 PAF, 3 
PsAF/LS PsAF 
Incision and cryo; 
Box, MI, CTI 
 100% isolated at 6-day EP study. One late 
recurrence of AF – gap in cryo line.  
“The unique data collected from these 
patients support the principle of isolation of 
the pulmonary veins and posterior LA as a 
curative therapy, regardless of the method 
used” 
1 pleural effusion 
Sueda et al.140 
Case series 
49 LS PsAF Incision and cryo/RF  Not stated 30% AF recurrence. No EP findings 
provided.  
Nil relevant.  Nil 
Garcia et al.119 
Case series 
30: 14 PAF, 16 
PsAF / LS PsAF 
HIFU Not checked 40% arrhythmia recurrence (AF n=6, left 
atrial flutter n=4, typical flutter n=2).  
Of those with arrhythmia freedom, 25% 
had isolated PW at EP study 
Gaps tended to be near the RSPV where the 
HIFU device is closed and are globally more 
prevalent when a larger cinch device was 
used. 
Nil 
Hybrid Based 
Pison et al.141 23; 1 LSP AF, 9 
PsAF, 13 PAF 
RF: WACA, roof and 
floor line  
100% 2 patients redo: one with flutter and one AF 
(gap in ring) 
“A combined transvenous endocardial and 
thoracoscopic epicardial ablation procedure 
for paroxysmal and recent persistent AF 
resistant to AADs has a single-procedure 
success rate of 83% at 1 year.” 
1 pleural effusion  
1 hospitalized for 13 days -
chest pain at the insertion 
sites 
Bisleri et al.131  
Case series 
45 LS PsAF Epicardial RF: Box  100% exit block  
91.1% entrance 
block 
No correlation made between rhythm and 
EP findings at time of second stage. 
92.6% freedom from AF in those with 
documented PW isolation at 28-month 
follow-up. 
Nil 
Table 3-3. Summary of the previous studies reporting invasive electrophysiological findings following ablation strategies intending to achieve posterior 
wall isolation. (AFl = Atrial flutter, AT = Atrial tachycardia, Box = Box-set lesion, Cryo = Cryoablation, CTI = Carvotricuspid isthmus, EP = 
Electrophysiology, HIFU = high intensity focussed ultrasound, LSP AF = Long-standing persistent atrial fibrillation, MI = Mitral isthmus, PAF = 
Paroxysmal atrial fibrillation, PsAF = Persistent atrial fibrillation, PWI = Posterior wall isolation, RF = Radiofrequency, RSPV = right superior 
pulmonary vein, WACA = Wide area circumferential ablation). 
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3.4.1 Previous Studies on the Box-set.  
Possibly the first published attempt a box pattern using catheters was Ernst et al. in 1999.102 
Unfortunately, the limited technology available at that time resulted in failure to achieve 
PWI in all of their cases. Todd et al. describes the initial 2003 experience following the 
combined open-chest surgical and catheter cryoablation box pattern for AF.103 At 6-days 
post procedure, all cases had persistently intact posterior wall isolation, determined through 
epicardial wires. Late recurrent of atrial arrhythmias in one patient resulted in 
electrophysiological restudy; a gap was found in the posterior wall isolation, closure of 
which restored sinus rhythm.  Todd demonstrated that the isolated PW was able to sustain 
atrial arrhythmia independent of the remaining atria; a finding that has been replicated in our 
study (3.3.4.1, 3.3.4.2).  
Lim et al. provides a comprehensive assessment of the mechanisms of arrhythmia recurrence 
following single ring ablation delivered by catheter.106 In 100 patients with an end-point of 
validated PWI, 69% experienced recurrence of an atrial arrhythmia (35% AF and 34% 
flutter). In those patients that underwent a redo procedure for recurrent AF, all had gaps in 
the ablation ring with conduction in and out of this region. In six of the patients, a flutter 
circuit was established through two gaps in the ring. Four patients had atrial flutter without 
evidence of AF and were found to have intact isolation of the posterior wall. The authors 
concluded that “electrically isolating the posterior LA may thus prevent the initiation and 
perpetuation of AF”. This agrees with the findings in our patients to mean follow-up of 63-
months. 
Tamborero et al.136 randomised patients undergoing AF ablation to receive PV-encircling 
lesions and roof-line alone or supplemented with a floor line to complete the box-set. A redo 
procedure was performed in 20% of their patients, and in 67% of initial PWI group, 
conduction across the roof-line was seen, suggesting that failure of the PWI model was in 
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part due to reconnection. They found no advantage to PWI attempted through the addition of 
a floor line compared to PV-encircling lesions and roof-line only.  
Sanders et al. provide a rare example of AF recurrence in one of 27 patients following box 
isolation in whom the PWI remained intact at restudy.138 That index patient required 
additional “substrate modification” to restore sinus rhythm.     
Kumagi et al.137 studied a purely paroxysmal group who, at mean follow-up of 13 months 
following catheter box-set ablation, showed a 95% rate of freedom from AF. Six of these 
patients required a redo procedure, three for recurrences of AF and the others from 
organised/focal arrhythmia. In all cases of recurrence, gaps in the lesions lines were seen. In 
none of these cases of recurrence was the PW found to be isolated. 
A recent resurgence in interest in the box pattern has come about as a result of the 
development of hybrid AF ablation techniques. These studies have the potential to offer 
some further insight into the electrical consequences of a single ring approach.131 To date, 
little has been published on the association between on-going AF prior to the second 
(catheter) stage of the hybrid pathway and the subsequent EP findings. As technology 
matures, this is a key opportunity to gaining a greater appreciation into the mechanisms of 
PsAF.  
3.5 Findings of This Study 
Although the EP findings in patients with recurrent atrial arrhythmia following box isolation 
have previously been described (Table 3-3), much less is known about long term invasive 
findings, especially in the group of patients with no recurrent arrhythmia. The bulk of the 
previous data comes from reports of patients undergoing transseptal procedures for 
organised atria arrhythmias. In the six patients free from AF in this present study, 4 had 
complete isolation of the PW, one had very delayed conduction through one gap near the 
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right upper PV and one (who had experienced very little AF prior to surgery) had a non-
isolated PW. The only patient who was AF free and was found to have a non-isolated PW 
was the only patient in the study with infrequent paroxysmal AF prior to surgery. This is 
maybe the reason for the clinical success despite the apparent electrophysiological failure. It 
may be that in such patients it is sufficient merely to modify the conduction without 
necessarily achieving complete PWI for successful outcome.  
Perhaps more interesting is our observation that in none of the patients with post-operative 
AF was the PW isolation found to be intact. It can thus be reasoned that the primary reason 
for failure to secure sinus rhythm is the failure of the technology used to deliver a complete 
transmural ablation ring, rather than the inappropriateness of the lesion pattern itself.  
3.6 Limitations of Study 
The aim of this study was to correlate the late clinical outcome with the electrical properties 
of the PW. The study achieved this endpoint. However, there are several limitations. Most 
significant is the low numbers included; a total of 17 patients of which only 6 had freedom 
from AF. This is in part due to the reluctance of patients with a clinically excellent outcome 
to undertake a further invasive procedure for no personal gain. The patient information 
provided was necessarily very comprehensive in describing potential adverse outcomes from 
what was on their part an entirely altruistic agreement to be studied.  We observed a 
significant attrition rate during the waiting period between agreeing to enter the study and 
planned study date. All 31 patients who were contactable and eligible for inclusion in the 
sinus rhythm group were approached.  
Secondly, we would have hoped to gain an appreciation of the role of the ganglionic plexi 
(GP) in AF propagation post epicardial HIFU ablation. GP stimulation was excluded from 
the present study protocol. No initial ‘roadmap’ of their location had been made at time of 
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surgery to guide which sites to address with high frequency stimulation. To attempt to 
stimulate all potential areas to would have prolonged the procedure beyond what was 
reasonable for these patients who had agreed to be studied under conscious sedation.  
3.7 Conclusions 
At long term follow-up, the decisive feature determining whether PW isolation results in 
freedom from recurrence of AF appears to be either intact isolation of the area or extreme 
functional delay of conduction into and out of the box-set. 
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4 THE RELATIONSHIP BETWEEN LEFT ATRIAL PRESSURE 
AND BODY MASS INDEX 
4.1 Introduction 
There are many diseases processes associated with an increase in prevalence of AF. It was 
generally thought that these were processes that tended to alter the pressure load on the LA, 
leading to an increase wall stress, fibrosis and ultimately fibrillation. Common examples 
include mitral valve and hypertensive heart disease. Other conditions act through more 
refined pathways; 15% of patients with hyperthyroidism develop AF.142 Proposed 
mechanisms for this include elevation of LA pressure secondary to increased left ventricular 
mass and impaired ventricular relaxation,143 ischemia resulting from raised resting heart rate, 
and increased atrial ectopic activity.144 
For a long time, obesity has been considered by many to be an independent risk factor for the 
development of AF. The mechanism of action is likely to be complex and involve multiple 
pathways. Conditions associated with obesity are themselves recognized risk factors for AF; 
hypertension, diabetes and obstructive sleep apnoea to name a few.  
The LEGACY study investigates the relationship between BMI and AF burden.124 The 
authors offered 415 patients with a BMI of >27kg/m2 and AF the chance to participate in a 
weight reduction program. Outcomes are reported in three main groups; less than 3% weight 
reduction, 3 to 9% weight reduction and greater than 10%.  They reported a statistically 
significant reduction in AF burden with weight loss. 
Pathak et al. provide a comprehensive discussion on possible mechanisms of action of the 
link between BMI and AF. Factors such as obstructive sleep apnoea, inflammation, 
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pericardial fat and diabetes are all suggested as associated co-morbidities. In section 2.3.3 we 
report that the BMI of the HIFU cohort was an independent risk factor for AF recurrence 
following ablation when analysis was corrected for both LA size and AF grade (p=0.036, 
OR  0.87 ( 0.78-0.99)). We hypothesised that this effect was mediated, at least in part, through 
an elevation in the LA pressure. 
To investigate this, we aimed to assess the relationship between mean LA pressure and BMI 
in an AF ablation cohort. We hypothesised that there would be a positive correlation 
between the two variables. In this two centre retrospective study, we collected data from 
transseptal studies in patients who have undergone AF ablation and compared them with the 
BMI at time of procedure.  
4.2 Methods 
156 consecutive patients from two high-volume sites (Derriford Hospital Plymouth and the 
Bristol Heart Institute) were included in the study. BMI data was retrospectively collected 
from the electronic databases. Mean LA pressure was determined using data recorded on 
Mac Lab following successful transseptal puncture. Readings was taken when clear steady-
state pressure have been achieved. An example is shown in Figure 4-1. As the interpretation 
of pressure tracings was subjective, pressures was recorded independently by two 
experienced observers.  Both took readings from the same set of pressure tracings and 
recorded them without collaboration. We performed intra class correlation analysis to check 
for observer reliability.  
4.2.1 Statistical Analysis 
A scatter plot was produced charting LA pressure and BMI.  Visual assessment identified 
outliers in both data points; we elected to use Spearman’s Rank correlation for analysis. A p 
< 0.05 was considered statistically significant.  Subgroup analysis was performed by 
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selectively running analysis excluding patients with specific characteristics (on ACE 
inhibitors, type of sedation and hypertension). Intra-observer reliability was assessed using 
Cronbach’s alpha.  
Figure 4-1. Example of a pressure tracing taken during AF ablation. The top tracing 
depicts the arterial waveform. The left atrial pressure is shown on the middle curve with 
both a real-time and mean trace. The bottom curve illustrates the real-time and mean 
pressure of the right atrium. In this example, the men left atrial pressure was judged to 
be 17mmHg by one observer and 18mmHg by the second.  
 
4.3 Results 
A total of 156 patients were included in the study. The procedures were performed between 
2009 and 2015. Patient baseline demographics are shown in Table 4-1. Additional analysis 
was performed by excluding certain individual patient groups; these also failed to show any 
clinically meaningful correlation. These results are shown in Table 4-2. 
Analysis of intra-observer variability was used to check for the reliability of the left atrial 
pressure recordings. Cronbach’s alpha was 0.993, showing an excellent degree of agreement 
between the 2 independent observers.   
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Table 4-1. Baseline demographics of study patient population (ACEi = Angiotensin 
Converting Enzyme Inhibitor, BMI = Body mass Index, OSA = Obstructive Sleep 
Apnoea). 
 
 
 
 
 
 
Table 4-2. Correlation values with the exclusion of specified patient groups (ACEi = 
Angiotensin Converting Enzyme Inhibitor, OSA = Obstructive Sleep Apnoea)  
 
 
 
Demographic N (%) 
Age/years 60.0 (9.2) 
Male: Female  
BMI 28.5 (4.0) 
OSA 27 (17.3) 
Hypertension 95 (61) 
Diabetes 14 (9) 
Smoker 32 (21) 
ACEi 56 (36) 
Betablockers 93 (60) 
Excluded Parameter Spearman’s Rank 
Correlation 
p Value 
ACEi 0.146 0.155 
Betablocker 0.276 0.036 
OSA 0.136 0.139 
Smoker 0.157 0.090 
Hypertension 0.227 0.081 
Normotensive -0.020 0.854 
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Figure 4-2. Scatterplot representation of the association between BMI and mean LA 
pressure. A line of best fit is shown (BMI = Body mass Index) 
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4.4 Discussion 
The improvement in outcomes from invasive AF management has resulted not only from a 
better appreciation of what constitutes an appropriate lesion set, but also from an improved 
understanding of the importance of patient selection. Patient characteristics that confer a poor 
outcome from medical and ablative strategies have been well-documented and there are a 
multitude of prognostic markers for the success of ablative procedures. Age, AF phenotype, 
LV impairment, dilated LA, comorbidities such as sleep apnoea, obesity, hypertension, LA 
fibrosis, and inflammatory markers have all been shown to be independent markers for a 
poor outcome.145–147 
 Not only does obesity convey a risk of recurrence following an AF ablation procedure, but it 
is also an independent risk factor for de novo AF onset. A recent population study of over 
18,000 patients showed that every 1 kg/m2 reduction in BMI during follow-up was 
associated with a 7% reduction in the risk of first time AF occurrence.148  
The link between obesity and AF is complex. Some theories suggest that is mediated 
primarily through an elevation in the LVEDP which in turn causes an increase in the mean 
LA pressure. This small study aimed to investigate whether the association between BMI 
and AF was mediated through an increase in LA pressure. Through the analysis of 156 
consecutive patients, we have failed to demonstrate any such meaningful correlation 
between the two parameters.   
It is likely that the mechanistic link is far more complex. For example, another well-
established comorbidity is obstructive sleep apnoea (OSA), which is itself closely correlated 
with BMI. It may be that OSA acts directly through elevation in LA pressure or through 
persistent hypoxemia, hypercapnia and surges in sympathetic tone.149 Pericardial fat which 
increases in obesity has also been associated with AF, both in the pre- and post ablation 
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setting. Again, the mechanism by which pericardial fat becomes pro-arrhythmic is unclear 
but may involve adipose infiltration of the myocardium or more complex inflammatory 
pathways.150 The GPs which supply the autonomic control to the myocardium are encased in 
epicardial fat. It has been suggested that increase in fat coverage enhances proarrhythmic 
behaviour mediated by both the sympathetic and parasympathetic systems, but much work is 
needed to clearly define these pathological processes.    
It is possible that our findings have failed to detect a genuine association.  Haemodynamics 
during an ablation procedure differ to those during ‘real life’; the patients are either heavily 
sedated or under a general anaesthetic. Both anaesthesia delivered through propofol or 
sedation via benzodiazepines can lead to a decrease in the systemic vascular resistance 
resulting in a drop in afterload with usually little or no compensatory increase in stroke 
volume or heart rate.151  
There are weaknesses in this analysis. Most importantly, we have failed to take into account 
the degree of mitral valve disease, the severity of which will tend to increase mean LA 
pressure, independent of BMI. That said, very few patients with haemodynamically 
significant MR are accepted for AF ablation, so this should not have exerted a great skew 
effect on our analysis. Correlation analysis through Spearman’s rank will also tend to 
account for this small number of potential outliers.  
Based on these findings, it is likely that the mechanism of influence between BMI and AF is 
mediated through more complex pathways than merely elevation in mean LA pressure, 
though this may still play some part.  
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5 PERSISTENT ATRIAL FIBRILLATION ABLATION USING 
THE TIP-VERSATILE ABLATION CATHETER 
5.1 Introduction 
For patients with PsAF, the debate over the optimal ablative lesion set continues. PVI alone 
may be an inadequate solution with only 48% arrhythmia free off AAD at 18 follow up in 
the recently reported STAR AF II trial.71 There is a spectrum of additional approaches 
currently being deployed to achieve the substrate modification required to improve PsAF 
ablation outcomes (section 1.3).22 Strategies have been combining PVI with roof and mitral 
isthmus lines, targeting putative rotors, CFAEs or areas of low voltage, or ablating the 
GP.22,71 All have been reported to give largely similar success rates.71,152  
Surgical (epicardial) ablation is being revisited, particularly in selected patients with 
unfavourable anatomy or during concomitant cardiac surgery. Many of these surgical 
approaches aim to deliver the box-set lesion pattern. There is a growing body of evidence to 
suggest that this empirical pattern is effective in abolishing PsAF.153 Groups are now 
examining the role that this lesion pattern has to play in catheter ablation.105,154,155 
Between 2009 and 2013, we investigated deploying lesions in a box-set pattern from a 
purely endocardial approach using a combination of the Pulmonary Vein Isolation Catheter 
(PVAC) and the Tip-Versatile Ablation Catheter (T-VAC, Medtronic, Inc.). Here, we report 
our experience to date including a comprehensive description of the technique, complication 
rate, long-term (>1 year) outcome and procedural limitations. Outcomes from first time (‘de 
novo’) and all including redo procedures (‘all procedures’) are reported.  
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5.2 Methods 
5.2.1 The Patients 
Forty consecutive patients with symptomatic, drug resistant PsAF who had undergone 44 
ablation procedures between the years of 2009 and 2013 at our institution were 
retrospectively entered onto a database. Eligible procedures were identified by a data search 
through the local procedure database. PsAF was defined as any single episode that lasted 
greater than 7 days.22 Characteristics such as LA size and duration of AF had been 
considered when selecting patients for an ablation procedure, though no formal parameters 
were applied. Baseline characteristics are shown in Table 5-1. 
The primary endpoint was freedom from atrial arrhythmia (all arrhythmia and AF only) at 
late (>1 year) follow-up off AAD. Secondary endpoints were time to first arrhythmia 
recurrence post 3-month blanking period, freedom from atrial arrhythmia on and off AAD, 
procedural and fluoroscopy duration and complication rate.  
 The study was performed in accordance with the Declaration of Helsinki and with the 
approval of the local research and development department and Queen’s Square ethics 
committee. The written informed consent of the participants who required further rhythm 
monitoring as part of the study was obtained.  
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 All procedures (n=44) de novo (n=27) p value 
Age/years 56 (11) 57 (12) 0.77 
Male 37 (84) 21 (78) 0.62 
BMI 28.6 (4.0) 28.1 (3.6) 0.66 
Diabetes 2 (4.5) 2 (7.4) 0.63 
CAD 2 (4.5) 1 (3.7) 1.00 
SHD 4 (9.1) 3 (11.1) 1.00 
Hypertension 17 (38.6) 9 (33.3) 0.65 
Stroke 3 (6.8) 1 (3.7) 1.00 
OSA 1 (2.5) 1 (3.7) 1.00 
Amiodarone 
refractory AF 16 (36.4) 11 (40.7) 0.71 
Duration of 
AF/months* 62 (66.5) 41 (30.7) 0.18 
LA Vol / cm3 148 (44.3) 150 (44) 0.89 
Table 5-1. Baseline demographics of the T-VAC ‘de novo’ and ‘all procedure’ groups 
with inter group differences. (AF = Atrial fibrillation, BMI = Body Mass index, CAD = 
Coronary artery disease, LA Vol = Left atrial volume, OSA = Obstructive sleep apnoea, 
SHD = Structural heart disease). *Data expressed as median and (Inter Quartile 
Range) for non-normally distributed data. 
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5.2.2 Ablation Procedures 
Historic ablation was performed under either general anaesthesia or with IV sedation. Access 
was obtained via the right femoral and subclavian / internal jugular vein. Anticoagulation 
was delivered by either warfarin discontinued and bridged by low-molecular weight heparin 
(pre-2010), or uninterrupted oral anticoagulation with a target INR of 2.0 to 3.0. Heparin was 
administered intravenously following successful transseptal puncture to maintain the 
activated clotting time (ACT) at >300 seconds. Transseptal sheaths were continually flushed 
with heparinised saline (2 ml/min). Procedural duration was defined as the time between first 
needle insertion and final sheath removal. Cumulative fluoroscopy duration and 
radiofrequency energy dose and duration were recorded at the end of the procedure.  
5.2.2.1 Multielectrode Ablation Catheter (T-VAC) Technique 
Pulmonary vein isolation (PVI) using PVAC has been described previously.156 Briefly, 
following successful transseptal puncture, a 9F sheath (Channel, Bard Electrophysiology) 
was positioned into the left atrium to allow selective venography of all four pulmonary veins 
(PV). The PVAC catheter was deployed via the channel sheath to sequentially isolate all 4 
PVs; catheter was placed 1.0cm into the PV and baseline PV electrogram recordings were 
made (5 bipolar recordings, 16 x amplification and filter settings 100-500Hz). This was 
repeated during coronary sinus (CS)-pacing. The pacing threshold for capture via the PVAC 
catheter within the PV was measured prior to ablation. The PVAC was then placed on the 
antrum of the PV and the optimal rotational position was found to maximise contact. Energy 
was applied over a 60 second period with a target temperature of 60°C. Applications were 
made using 4:1 mode. In general, 4 applications were made per vein rotating the catheter to 
ensure arcs of ablation overlapped around the circumference of the PV antrum. Entry block 
was indicated by abolition of the pulmonary vein potentials (PVPs) observed prior to 
ablation within the vein. When all PVs appeared isolated the PVAC catheter was removed. 
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Following removal of the PVAC catheter, the T-VAC catheter was inserted into the LA via 
the steerable sheath. The T-VAC catheter is a steerable linear ablation catheter with 6 
electrodes capable of independently delivering unipolar or bipolar energy. Starting at the 
junction of the right upper pulmonary vein, sequential linear lesions were made in a sweep 
across the left atrial roof to the left sided veins. The catheter was then deployed at the lateral 
LA wall with the tip extending to the isolated area of the left lower pulmonary vein and 
applications made in a line directed towards the coronary sinus. Here, the catheter was 
directed parallel to the CS and then across the LA floor to the right sided PVs before being 
brought up to complete the encircling of the PVs and the PW via the interatrial septum 
anterior to the right sided veins (Figure 5-1). In 3 cases the lesion pattern was mapped using 
the LocaLisa 3D mapping system (Figure 5-2). Each application was for 60 seconds using a 
2:1 mode and a target temperature of 60°C.  The empirical deployment of T-VAC was 
guided purely by single plane fluoroscopy. Total energy delivery durations are shown in 
Table 5-2. 
Complete electrical isolation of the PW was not validated in any of the cases. Additional 
ablation was performed in areas with dense CFAE (defined visually as local continuous 
deflections with multiple components crossing the baseline) where these were observed 
during catheter movements.  
In cases where typical right atrial flutter had previously been documented, a carvotricuspid 
isthmus (CTI) line was performed in the RA. This was done in most cases using the T-VAC 
catheter in a reverse configuration.  
PV isolation was then re-checked and additional ablation delivered as required. In addition to 
confirming absence of conducted PVPs in NSR, exit block was confirmed by pacing via the 
PVAC catheter within the PV. Acute procedural success was defined as exit and entry block 
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from the pulmonary veins together with the empirical deployment of T-VAC linear lesions. 
Electrical isolation of the PW was not sought as a procedural endpoint. 
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Figure 5-1. Fluoroscopy images of the T-VAC deployment: left atrial roof to the left sided veins (A, B); lateral LA wall to the isolated area of the left 
lower pulmonary vein directed towards the coronary sinus (C-E); directed parallel to the CS (F) and then across the floor of the LA to the right sided 
veins (G) before (H) being brought up to complete the encircling of the PVs and the posterior wall via the interatrial septum anterior to the right sided 
veins (I&J). Reproduced from Davies et al. with permission.157  
 
E D C B A 
J G H I F 
 94 
 
 
 
 
Figure 5-2. PVAC and T-VAC lesion patterns displayed using LocaLisa 3D system. 
Although we were able to use the software to depict the T-VAC catheter, the red 
lesions were added manually. In this case, the integrity of the box-set appears 
complete but posterior wall isolation was not achieved. Reproduced from Davies et al. 
with permission.157  
5.2.3 Post Procedural Management  
AADs were continued throughout the 3-month blanking period and then withdrawn at the 
discretion of the managing physician. DCCV was offered for sustained symptomatic 
arrhythmia throughout the blanking period; these were not recorded as procedural failure. 
Follow-up was performed at 3, 6 and 12 months with a standard 12-lead electrocardiogram 
and additional symptom driven ambulatory monitoring where required. During the late 
follow-up visit, those patients in NSR were asked to undergo a 6-day period of ambulatory 
monitoring (Spiderflash, Sorin) to exclude atrial arrhythmia. NSR was defined as freedom 
from AF or AFl lasting >30 seconds.22 The follow-up restarted when a patient underwent a 
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redo ablation procedure and in the further follow-up they were recorded as single-procedure 
failures.  
5.2.4 Follow-up and Data Capture 
The data was collected retrospectively. A database was constructed to capture all case 
variables. The cases were identified as described in 5.2.1. All 40 patients remained under 
active follow-up. If an existing clinic appointment was scheduled for within 6 months, this 
was kept; otherwise patients were invited to be reviewed in an additional research clinic. 
During this clinic visit, the accuracy of the baseline demographic data was checked, drug 
history was recorded (including details on all AADs) and symptoms were investigated. A 
12-lead ECG was used to check the heart rhythm. Any patient in NSR at this clinic 
appointment was invited to undergo a 6-day ambulatory ECG to confirm the absence of 
atrial arrhythmia.  
Final outcomes were recorded according to the following definitions: 
• AF: In AF on the 12 lead ECG with no electrocardiographic evidence of or 
symptoms suggesting NSR in the past 6 months. 
• PAF: In NSR at the time of clinic ECG but with evidence of >30 seconds of AF on 
the ambulatory event monitor22 or in NSR in clinic but with ECG evidence of AF 
within the past 6 months. 
• AFl: Any ECG evidence of atrial flutter or atrial tachycardia within 6 months of 
follow-up.  
• NSR: Both in NSR at the time of clinic and with no evidence of atrial arrhythmia on 
6-day ambulatory event monitor.   
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In addition to taking a comprehensive symptom history, all available records were searched 
for evidence of arrhythmia. This included, but was not limited to, the hospital notes from 
Derriford and surrounding DGHs, all electronic notes and GP records (enquired via 
telephone). This data was used to record the time to first atrial arrhythmia recurrence.   
5.2.5 Statistical Analysis 
Categorical variables are presented by percentages. Numerical variables were tested for 
normality using Shapiro-Wilk and are expressed either as mean and standard deviation (SD) 
for normally distributed data or median and interquartile range (IQR) for non-normal data. 
Between group differences were assessed by independent samples t-test, Chi squared 
(Fischer’s exact test when any cell number was ≤5) or Mann-Whitney where appropriate. 
The Kaplan–Meier method was used for the event-free survival curve; follow-up was 
censored at the first arrhythmia recurrence or last arrhythmia-free clinic visit, whichever 
came first. A p value <0.05 was considered statistically significant. Data analyses were 
performed using the IBM SPSS v21.  
5.3 Results 
5.3.1 ‘De novo’ and ‘all procedures’ 
Between 2009 and 2013, 44 procedures were performed on 40 patients; 27 procedures were 
de novo cases, the other 17 had previously undergone AF ablation using a variety of 
technologies (9 wide area circumferential ablation, 1 surgical HIFU, 3 duty cycled RF PVI 
and 4 PVAC & T-VAC redos). All had documented PsAF prior to the procedure. The 
baseline demographics for the ‘de novo only’ and ‘all procedures’ are shown in Table 5-1. 
Follow-up data is available on all 40 patients eligible for inclusion in the study.  
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Outcome All procedures (n=44) 
De novo 
(n=27) p value 
NSR 23 (52) 16 (60)  
NSR off AAD 22 (50) 16 (60)  
PAF 7 (16) 4 (15)  
PAF off AAD 5 (11) 4 (15)  
PsAF 11 (25) 5 (19)  
PsAF off AAD 11 (25) 4 (15)  
Atrial Flutter 3 (7) 2 (7)  
Atrial Flutter off AAD 2 (5) 2 (7)  
Follow-up / months 38 (13) 37 (14) 0.95 
DCCV during 
blanking period 7 (16) 5 (19) 0.75 
CCV during blanking 
period 2 (5) 2 (7) 0.63 
DCCV following 
blanking period 13 (30) 8 (30) 1.00 
CCV following 
blanking period 4 (9) 3 (11) 1.00 
AAD post blanking 
period 12 (27) 10 (37)  
Total energy time / 
seconds 2190 (931) 2239 (883) 0.82 
Total fluoro time / 
minutes 60.6 (11.7) 60.2 (10.0) 0.88 
Catheter procedure 
duration / minutes 193 (35) 191 (25) 0.80 
Table 5-2. ‘De novo’ and ‘all procedures’ outcomes (data expressed at n (%)). (AAD = 
Antiarrhythmic drugs, NSR = Normal sinus rhythm, AF = Atrial fibrillation, AFl = Atrial 
flutter, AT = Atrial tachycardia, CCV = Chemical cardioversion, DCCV = DC 
cardioversion, NSR = Normal sinus rhythm, PAF = paroxysmal atrial fibrillation, PsAF = 
Persistent atrial fibrillation) 
5.3.1.1 Procedural Data 
There was no difference in the type of anaesthesia between the ‘de-novo’ and ‘all 
procedures’ groups (44.4% vs 43.2% general anaesthesia, p=0.92). 
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Procedure time was 193 ± 35 minutes (192 ± 25 minutes de novo, p=0.81), total energy 
delivered 2190 ± 931 seconds (2239 ± 883 de novo, p=0.82) and fluoroscopy time was 61 ± 
12minutes (60 ± 10 de novo, p=0.87). Twenty-four (54.5%) of the procedures included a 
concomitant CTI line (52% de novo, p=1.00).  
5.3.1.2 Long-term Outcome 
The mean follow duration was 33 (range 24-63) months. The absolute freedom from any 
atrial arrhythmia recurrence off AAD was 45% in the de novo group and 47% in all 
procedures group.  
All patients in symptom free NSR for at least three months at late follow-up underwent a six-
day event-monitor.22 Late follow-up outcomes are shown in Table 5-2. At mean follow-up, 
60% (52% of group 2) of patients remained in sustained NSR (60 and 50% respectively off 
AAD). A further 15% (16% of group 2) reported only occasional paroxysms of AF (15 and 
11% respectively off AAD). Overall, 75% of group one had either AF freedom or a change 
from persistent to paroxysmal following a single ablation procedure off AAD. Of the four 
cases that underwent two T-VAC procedures, two remain in AF and two now have PAF. Of 
the 17 cases that had previously undergone a LA ablation for AF, only 41% were free from 
AF at late follow-up.  
5.3.1.3 Time to First Event 
Following a blanking period of 3 months, the first documented arrhythmia recurrence was 
recorded (Figure 5-3 & 5-4). Univariate analysis showed no effect of LA size or total 
duration of AF on likelihood of event free survival (OR 0.99 (0.98-1.01, p=0.64 and 1.0 
(0.99-1.01), p=0.58 respectively).  
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Figure 5-3. Kaplan-Meier plot showing the event free survival from all atrial arrhythmia 
between the all T-VAC procedures versus the de novo T-VAC group. Reproduced from 
Davies et al. with permission.157 
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Figure 5-4. Kaplan-Meier plot showing the atrial fibrillation free survival of all T-VAC 
procedures versus the de novo group. Reproduced from Davies et al. with 
permission.157 
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5.3.1.4 Redo Study Findings 
9 patients had previously undergone WACA ablation using point-by-point techniques and 3 
had PVI with the PVAC catheter. In all cases except 2, there was evidence of reconnection in 
between 1 and 4 PVs. Ablation strategy remained to re-isolate the veins before completing 
the T-VAC catheter sweep. In the two cases where all 4 veins were isolated at the start of the 
procedure, the operator proceeded directly onto posterior wall ablation. In one of these cases, 
confirmed posterior wall isolation was achieved with the T-VAC; this patient was in NSR at 
long-term follow-up. In the other, confirmed PW isolation was not achieved; the patient 
suffered a relapse into PsAF. 
Of the 4 patients who underwent a redo procedure where the initial procedure was with T-
VAC, all 4 had at least one PV reconnected.  
5.3.2 Complications and Procedural Safety 
There were no major procedural related 30-day complications. In particular, no atrio-
esophageal fistulae, thromboembolic events or phrenic nerve paralyses were reported in any 
of the 44 ablation procedures.  
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5.4 Discussion 
These results show that PsAF ablation can be performed quickly and safely with the PVAC 
and T-VAC catheter combination with a long-term freedom from AF rate of around 60% of 
cases.  
5.4.1 Duty-cycled Radiofrequency in Persistent AF 
The efficacy of duty-cycled technology in paroxysmal AF ablation is proven.158 The limited 
work into it’s use in PsAF to date is summarised in Table 5-3. The only randomised 
controlled trial (TTOP-AF) compares duty-cycled ablation to medical management in PsAF 
patients.159 Their ablation technique employed three multi-electrode catheters: Multi-Array 
Ablation Catheter (MAAC), Multi-Array Septal Catheter (MASC) in addition to the PVAC 
catheter. They report a reduction in AF (defined as a reduction in AF burden of >90%) in 
around 71% of cases at 6-month follow-up in a cohort of patients broadly similar to ours but 
with a shorter history of AF (0.9 ± 0.9 vs. 38.5 ±27.7 months).  
Mulder et al. reported 50 of 89 (56%) patients with PsAF were free from AF/AFl lasting >30 
seconds after 1.2 procedures without AAD at 12-month follow-up using a 7-day ambulatory 
ECG.160 Similarly, Scharf et al. reported an 66% success rate (defined as a >80% reduction 
in AF burden) at 20 months, though 50% of patients required 2 procedures.161 Tivig et al. 
report a single procedure success rate of 46% at >1 year follow-up using the PVAC, MAAC 
and MASC combination, rising to 73% after multiple procedures.162  
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Table 5-3. Summary of case series reporting outcomes from persistent atrial fibrillation ablation using duty-cycled radio-frequency ablation. *Quoted 
data is for PsAF cases only.  (AAD = Anti-arrhythmic drugs, AF = Atrial fibrillation, AV = Arterio-venous, CFAE = Complex fractionated atrial 
electrograms, DC = Duty-cycled, LSP = Long-standing persistent atrial fibrillation, MAAC = multiarray ablation catheter, MASC = multiarray septal 
catheter, PAF = Paroxysmal atrial fibrillation, PVAC = Pulmonary vein ablation catheter, PVI = Pulmonary vein isolation, STEMI = ST elevation 
myocardial infarction, TIA = Transient ischaemic attack, TTOP-AF = Tailored Treatment of Persistent Atrial Fibrillation, 3D = 3-dimentional, PsAF = 
Persistent atrial fibrillation)   
Study, design Number Ablation 
catheters / 
technique 
Comparator Follow-up 
period/Method 
AF Outcome Complications 
TTOP-AF159 
International, 
multicentre RCT.  
138 DC Ablation, 
72 Medical 
management 
PVAC, MAAC & 
MASC. 
PVI and CFAE 
targeted ablation 
Medical 
Management (43 
cross-over to 
ablation) 
6 months 
7-day holter monitor 
>90% AF reduction: 
Ablation, 67.4%; Control, 
26.4% 
12.3% acute 
complication rate (2.9% 
stroke, 1.4% tamponade) 
Scharf et al.161 
Multicentre, 
single arm.  
50 (100% LS 
PsAF) 
PVAC, MAAC & 
MASC. 
PVI and CFAE 
targeted ablation 
None 6±1 months 
7-day holter monitor 
 
 
 
 
20±4 months 
7-day holter monitor 
>80% reduction in AF; 64% 
off AAD, 80% on AAD. 
Free of AF; 54% off AAD, 
70% on AAD. 
 
>80% reduction in AF; 47% 
off AAD, 66% on AAD 
Free of AF; 45% off AAD, 
60% on AAD. 
8% (2% haematoma, 2% 
AV fistulae, 2% 
tamponade & 2% 
stroke) 
Tivig et al.162 
2006-8 
Non-randomized, 
single centre.  
209 (143 PAF, 66 
PsAF) DC 
Ablation, 211 (155 
PAF, 56 PsAF) 
PVAC, MAAC & 
MASC. 
CFAE targeted 
ablation ± PVI 
Conventional 3D 
guided point-by-
point ablation.  
>6 months 
 
 
 
>12 months 
1 procedure success; 51% 
(57% control)* 
 
1 procedure success; 46% 
(61% control)* 
2.6% total (0.5% stroke 
in DC arm, 0.5% AV 
fistulae and 0.7% 
tamponade) 
Mulder et al.160  
Single arm, single 
centre. 
89 (100% LS 
PsAF) 
PVAC, MAAC & 
MASC. 
PVI and CFAE 
targeted ablation 
None 12 months 
7-day holter monitor 
Free of AF; 36% off AAD,  
On-going PAF; 17% 
Within 24 hours; 1 
STEMI & 1 haematoma 
>1 month; 1 TIA and 1 
pericardial effusion. 
 104 
5.4.2 Posterior Wall Ablation 
The lesion set used in this case series is based on the previously described concept of the 
‘box-set’ lesion pattern. Published evidence, both from surgical and catheter based series, 
have shown that the box-set is an effective lesion set for ablative management of PsAF. 
Sanders et al. report a 63% 2-year freedom from AF rate when combining WACA with a 
left atrial roof and floor line to produce validated PW isolation.138 Hybrid approaches, 
designed to deliver the box-set via both an epi- and endocardial approach in a staged fashion 
have reported freedom from AF outcomes as high as 89%.131  
Evidence from studies reporting redo procedures following previous catheter delivered 
single ring PW isolation showed that in patient with a recurrence of AF, all were found to 
have reconnection of ablation lines and an un-isolated PW.106 Furthermore, in all the studied 
patients with freedom from AF (and a recurrence of an organised atrial tachycardia) all were 
found to have an intact ablation ring.  This finding suggests at the importance of PW 
isolation in delivering freedom from AF. 
Our technique does not deliver validated PW isolation. It is possible therefore, that the 
observed outcome is due to conduction delay rather than complete isolation, though this 
would perhaps lead to more recurrences of atypical flutter than we observed. More work is 
required to ascertain the exact properties of the box-set required for successful outcome. One 
such randomised study comparing PVI alone to PVI plus PW isolation is due to complete in 
2016 and should help define box-set requirements.154  
5.4.3 Pulmonary Vein Isolation 
PVI alone is generally considered insufficient to successfully ablate PsAF - further substrate 
modification is needed.22 However, several series looking at the importance of PVI in this 
tandem approach suggests that it is an important component of the overall procedure. One 
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such study reported the electrophysiological findings at redo procedure following previous 
PVI and substrate modification.163 In all cases of AF recurrence, at least one of the PVs had 
reconnected, and following re-isolation, good long-term outcomes were seen. The fact that in 
our series, validated block of all 4 PVs was achieved is likely to be an imported aspect of our 
lesion pattern.  
5.4.4 Ganglionic Plexi 
Though more work has yet to be done in the area, there is growing evidence to support the 
role of the ganglionic plexi (GP) in the initiation maintenance of PsAF.164 There is evidence 
to suggest that wide area circumferential or single ring ablation techniques can alter those GP 
adjacent the pulmonary veins.165 Furthermore, bilateral GP ablation can positively affect 
procedural outcomes.166 Previous groups have established the common anatomical sites for 
these GPs.167 There are clusters in the right atrium that will remain unaffected by our 
technique, but other areas in the left atrium tend to cluster along those areas empirically 
ablated using the T-VAC technique.78,163 We did not map out the GPs or intentionally target 
them during our approach, but it is possible that the irreversible alteration or destruction of 
GPs positively influences the long-term outcome of our procedure.78,165 Further work is 
required to compare residual autonomic function between the 2 groups.  
5.4.5 Comments of Technique 
The empirical pattern delivered in this study was reproducible under fluoroscopic guidance 
and used only 2 multi-electrode ablation catheters compared to 3 in the PVAC, MAAC and 
MASC series;159,161,162 an important consideration in the current economical climate.  
The T-VAC catheter is not currently supported by any of the current 3D imaging 
technologies such as CARTO™ (Biosense Webster) or Ensite-NavX™ (St. Jude Medical). 
This means that ensuring continuity of the individual lines into a continuous box lesion is 
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problematic. In 3 T-VAC cases, we trialled the use of the first generation LocaLisa 3D-
mapping system (Medtronic Inc., Figure 5-2).  Though we were able to track the catheter 
movement and mark areas of ablation delivery, overall the system resolution was not 
sufficient to reliably ensure integrity of the box-set.   
Because our novel technique does not utilise a mapping system, it is inherently more suitable 
for sedation cases compared to point-by-point techniques which conversely rely heavily on 
the patient remaining static throughout the procedure. Cases performed under sedation are, in 
our experience, less expensive than those involving general anaesthesia, an important 
economic consideration. 
One significant problem with deployment of the T-VAC catheter was that in several 
positions where the operator intended to deploy the catheter, it was impossible to achieve 
sufficient catheter stability needed to guarantee contact across multiple ablating electrodes. 
Furthermore, there was a tendency for the catheter to slip down towards the floor of the left 
atrium around right septal positions and away from the posterior wall towards the mitral 
valve in left sided and central positions.  
Patient selection for PsAF ablation is of paramount importance.  It is important that various 
factors are taken into account when selecting a suitable patient cohort. Strong predictors of 
procedural success include body mass index, absence of underlying disorder (i.e. lone AF), 
LA atrial diameter, fibrosis and duration of AF.152 Though we did not assess for fibrosis, the 
patients in this series were relatively favourable with a mean LA volume of 146cm3 (normal 
approximately 88cm3).168 It is likely that this patient selection accounts at least in part for the 
favourable outcomes. This suggests that it may be possible to define a group of patients with 
PsAF that in combination with a suitable technique can give single procedure success rates 
in the region of 75%. 
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5.4.6 Study Limitations  
This study was neither prospective nor randomised in design. However, the patients included 
had characteristics similar to other series describing PsAF ablation techniques.138,161,162 
While a combination of 12-lead ECG and intermittent monitoring was used throughout 
routine follow-up, prolonged ambulatory monitoring was only performed at the index 
follow-up in those patients in NSR. The timing of this follow-up was highly variable which 
significantly degrades the comparability between this and other case series. Given the natural 
attrition rate of normal sinus rhythm following an ablation procedure, the heterogenicity of 
the follow-up period may furthermore weaken the strength of these results. Furthermore, as a 
result of this monitoring schedule, it is possible that some patients with PAF were incorrectly 
coded as PsAF. However, this would only serve to give a negative skew to the reported 
success rate.  
5.5 Conclusion 
Using this novel duty-cycled technique in patients with persistent AF, it is possible to 
achieve first time success rates commonly achieved using a 3-catheter approach, with a low 
complication rate.   
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6 DISCUSSION 
6.1 Original Findings  
In section 1.4, the reader was introduced to the stated aims of this thesis. These 4 main 
aspects have been reported in the preceding chapters.  
• The very long-term outcome from surgical AF ablation using the Epicor HIFU 
device has been found to be 81% for PAF, 56% in PsAF and 18% for LS PsAF. 
• There appears to be a link between long-term electrical isolation of the PW and 
freedom from AF. 
• There is no clear correlation between BMI and LA pressure suggesting a more 
complex mechanism of action. 
• Using this novel duty-cycled technique in patients with persistent AF, it is possible to 
achieve first time success rates commonly achieved using a 3-catheter approach, 
with a low complication rate. 
6.1.1 Outcomes from HIFU Surgical Ablation 
In line with other published data, the long-term outcome from AF ablation using the Epicor 
HIFU device was found to be dependent on the classification of pre-operative AF. For PAF, 
freedom from atrial arrhythmia was in the region of 80% whereas for those with LS PsAF, 
the figure was closer to 20%. This remarkable discrepancy is difficult to explain. By 
isolating the PVs and PW en bloc, the vast majority of what was traditionally considered the 
substrate for PAF and PsAF was isolated from the remainder of the heart. Only one ablation 
ring was delivered. Thus, an incompletely delivered lesion should have been equally 
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detrimental for all preoperative classes of AF; triggers would still be conducted from the PV 
to the PW substrate and AF would be conducted to the remained of the heart.  
The study by Todd et al.103 suggests that the box-set is an effective lesion pattern for ablative 
management of AF, yet in our cohort we report a relatively disappointing outcome. There 
are several possible reasons behind this observed effect; these can be thought of as either a 
failure of the lesion to control AF, or a failure of the technology to deliver the transmural 
lesion. Though groups have reported on the effectiveness of the lesion pattern, this is usually 
through observations made at the time of redo procedures and as such concentrates 
predominately on cases involving arrhythmia recurrence.  
In the second stage of this thesis, we aimed to study patients with both recurrence and 
freedom from AF in an attempt to delineate the relationship between the integrity of the box-
set pattern and procedural outcome. 
6.1.2 Effectiveness of Box-set Patterns 
Patients comprising the cohort described in chapter 2 (Table 2-2) were invited back for an 
invasive electrophysiological assessment. The electrical characteristics of the PW and PVs 
were reported. A total of 17 patients were studied: 11 with on-going AF and 6 with AF 
freedom. This ambitious study has several significant limitations but does lend support to the 
effectiveness of the box-set pattern. In none of the cases of AF recurrence was the PW found 
to be isolated; in the patients with long-term freedom from AF, four out of six had complete 
isolation of the posterior wall and a fifth patient had marked conduction delay in and out of 
the posterior wall. The remaining patient had shown relatively little AF prior to surgery. 
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6.1.2.1 Study Challenges 
6.1.2.1.1 Recruitment 
The numbers in this study were smaller than initially planned, exclusively due to difficulties 
in recruiting in the sinus rhythm arm. Patients with sinus rhythm were understandably 
reluctant to participate in this study, as the consent process included a thorough and 
extensive explanation dwelling on the small chance of serious complications from invasive 
studies. Some hesitated through the inherent risk of the study and the trans-septal puncture. 
Others held the belief that the study may initiate refractory AF and some did not wish to be 
restarted on anticoagulation.  
The sinus rhythm pool was also found to be smaller than initially thought as a result of the 
attrition rate inherent in many AF ablation outcome studies; freedom from AF 4 years 
following ablation is no guarantee of on-going freedom. Some of those reported to be in 
NSR in the study reported in chapter 2 were found to have relapsed into AF when the 
screening was performed for chapter 3; there was approximately 12-18 months between 
these 2 time points. This delay was in part due to the challenges in securing appropriate 
funding for the study and also due to the necessary restrictions put in place by the regional 
ethics committee. As part of their agreement for us to perform this trial, the REC required all 
20 patients to be recruited (10 with on-going AF and 10 with normal sinus rhythm) before 
the first underwent the invasive study. Though we were able to satisfy this requirement with 
at one point having successfully recruited 21 patients, there was a significant dropout rate 
between the time of recruitment and study; 6 patients withdrew in this timeframe. We found 
that the dropout rate was significantly lower when this timeframe was reduced. It appeared 
that the longer asymptomatic patients were given to reflect on study participation, the more 
likely they were to withdraw. 
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6.1.2.1.2 Electrophysiological Assessment 
In order to assess the electrical properties of the left atrium, we used 3 main technology 
platforms; assessment of electrograms via a circular mapping catheter with or without 
voltage maps obtained using either CARTO or NavX. Due to cost implications we were only 
able to use the complex 3D mapping strategies in cases where we intended to perform 
further ablation. Although the use of only a circular mapping mapping catheter cannot allow 
for scar mapping per se, it was certainly sufficient to describe the electrical properties of the 
posterior wall and pulmonary veins with a clarity sufficient for our purpose. 
Our use of the voltage mapping system had limitations and certain flaws. Firstly, inherent in 
all pre-contact force catheter era studies, the specificity of low voltage areas is reduced due 
to the issue of contact. We did not routinely use contact force mapping catheters due to the 
cost implications for the study. Secondly, some of our voltage maps were produced during 
AF. The general consensus of opinion is that these should ideally be produced during NSR.96 
The theoretical downside of using such techniques whilst mapping during AF is that the scar 
volume will be overestimated. While we recognise this potential flaw in our methodology, 
many of our patients had refractory AF (see Table 3-2) which prohibited optimal mapping.    
Lessons were learnt in those cases where further ablation was performed. There was one 
case of an atypical flutter that was found to be peri-mitral and in another case AF organised 
into a flutter on re-isolation of the pulmonary veins which subsequently terminated on 
completion of the roofline. Unfortunately one of the well described potential drawbacks of 
the box-set pattern is that it is potentially proarrhythmic for macro re-entrant circuits.106 A 
validated mitral isthmus line should be considered in all cases. 
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6.1.3 Linear Catheter Ablation 
6.1.3.1 Study Design and Recruitment 
PsAF ablation using T-VAC catheter has been performed in our centre since 2009. Our 
initial plan to investigate the effectiveness of this technique was to perform a prospective 
non-randomised pilot study in around 20 patients. However, with the introduction of contact 
force feedback catheters and the technological advancement of 3-D mapping systems, it was 
felt that these were potentially superior platforms with which to perform prospective box-set 
lesion studies. Subsequently, after discussion with the institutional research and development 
department, together with the regional ethics committee, it was considered ethically 
appropriate to use a retrospective design allowing a higher number of participants to be 
enrolled in a shortened and more feasible timeframe.  
6.1.3.2 Ablation Using T-VAC 
The T-VAC catheter has specific strengths and weaknesses for this role. Although in theory 
it is potentially able to deliver a full box lesion with 8 to 10 energy applications, catheter 
stability, manipulation and tissue contact were found to be suboptimal. There were many 
occasions where the catheter could not be placed as desired onto the floor of the left atrium 
and tended to slip into the mitral orifice. Anchoring of the catheter tip was impossible.  
There was also the issue of mapping. The T-VAC catheter is not compatible with either 
CARTO or NavX; all cases were performed using fluoroscopy guidance only (except 2 
where we trialled the compatibility with the LocaLisa system, Figure 5-2). This meant that 
delivering a continuous single ring with no gaps was challenging. Indeed, true PW isolation 
was not obtained in any of the cases as far as we observed, nor was it an end-point of the 
procedure.  
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We have described a case in the previous chapters in whom PsAF was successfully treated 
by achieving only a significant conduction delay of the PW and not true isolation (case 5, 
Table 3-2). It is therefore possible that our T-VAC technique was successful in treating some 
cases of PsAF by delivering significant functional block only. It is equally a possibility 
however that there are other mechanisms explaining its limited success. For example, the 
paper by Rolf et al. describes the mapping and subsequent box ablation of areas of low 
voltage (scar).96 It is possible that chance ablation across these areas of low voltage is the 
mechanism of action in our successful cases. It is equally possible that we inadvertently 
modified the ganglionic plexi preferentially with the T-VAC catheter. The study by Garcia et 
al. also describes freedom from AF in patients treated with the Epicor system in who the 
posterior wall was found to be non-isolated.119 Much work is needed to determine the true 
part these factors have to play in the outcome of an AF ablation procedure.   
6.2 Future Directions of Study 
The three main projects in this thesis view the box-set lesion pattern from different angles. 
Though a clear link between PW isolation and freedom from AF has been observed, our 
work does not lend support to any of the competing mechanistic theories. During the 
completion of this thesis, hybrid AF ablation has become a mainstream ablation technique 
for patient with PsAF. Involving staged epicardial and endocardial procedures, this exciting 
technique should be viewed as an opportunity for further investigating the effect of PW 
isolation.  
The T-VAC catheter has been shown to be at least partially successful in delivering a lesion 
pattern based on the concept of the box-set. Further work is required in the development of 
more stable linear ablation catheters that are compatible with 3D mapping systems. Once this 
is available, a randomised prospective trial comparing box-set lesions delivered by linear or 
point-by-point with contact force mapping should more accurately assess these 2 techniques.  
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